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ABSTRACT 
 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of 
reproductive age women and has received substantial research time and financial 
support over the past few decades. Despite on-going research efforts, the etiology of this 
disease has not been elucidated. Many pre and post-natally androgenized animal 
models exist for this disorder but none completely recapitulate both the reproductive and 
metabolic features of the obese phenotype of PCOS with concomitant metabolic 
syndrome (MetS). Moreover, although PCOS is believed to arise from an interaction of 
heritable and non-heritable factors, there is no concrete evidence that in utero or 
environmental exposure to androgens forms the basis for the non-heritable aspect of its 
pathogenesis. This Ph.D. dissertation focused on the validation of the obese Ossabaw 
(OSS) pig as an animal model for the obese phenotype of PCOS with concomitant MetS. 
Unlike the currently available animal models for PCOS, this animal model incorporates 
both heritable (thrifty genotype breed) and non-heritable (obesogenic diet) components. 
The main findings of this work were that when OSS pigs were fed an excess calorie high 
fat/cholesterol/fructose diet: 1) both OSS sows and gilts developed android obesity and 
metabolic perturbations, including but not limited to dyslipidemia, hypertension and 
glucose intolerance, which met the Rotterdam Diagnostic Criteria for MetS; 2) both OSS 
sows and gilts developed persistent post-ovulatory size ovarian cysts; 3) both OSS sows 
(androstenedione only) and gilts (androstenedione and DHEAS) became 
hyperandrogenemic; 4) both OSS sows and gilts developed protracted estrous cycle 
length; 5) both OSS sows and gilts developed increased numbers of medium (3.5-6.5 
mm) and large (6.5-12.5 mm) size follicles during the luteal phase of the estrous cycle; 
6) OSS sows had increased LH and decreased progesterone serum concentrations; 6) 
OSS gilts had decreased LH and increased FSH serum concentrations throughout the 
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estrous cycle as well as increased progesterone serum concentrations during the luteal 
phase only; 7) OSS sows responded to a long-term GnRH agonist superovulation 
protocol similarly to OSS sows on a control diet; 8) the theca cells of OSS gilts did not 
demonstrate basal differences in the gene expression of steroidogenic enzymes but did 
respond to in vitro LH stimulation with increased production of androstenedione; 9) OSS 
gilts had an increased androgen:estrogen ratio in the follicular fluid and demonstrated 
down regulation of estrogen controlled genes on oocytes; 10) OSS gilts responded to an 
in vivo androgen challenge similarly to OSS gilts on a control diet. These findings 
demonstrate that both the obese OSS sow and gilt are excellent animal models for 
obesity and MetS in humans. There is also evidence that each of these animal model 
variations manifest some of the features of the obese phenotype of PCOS. However, 
based on the current evidence generated by this Ph.D. research neither of these model 
animals completely recapitulates all of the reproductive features of the obese phenotype 
of PCOS. It is possible that the obese OSS sow and/or gilt may be better suited as 
models of the effects of obesity on reproductive and endocrine physiology. Future 
research that examines the role of the adrenal gland and adipose tissue as well as 
expands on current knowledge of theca, granulosa, and oocyte physiology in this model 
animal will characterize further the molecular mechanisms underlying the biochemical 
and physical attributes of the obese OSS pig.   
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CHAPTER 1 
INTRODUCTION 
Polycystic ovary syndrome (PCOS) is the most prevalent female reproductive 
endocrine disorder, affecting approximately 5-10% of women [1-4]. It is defined as 
otherwise unexplained hyperandrogenic anovulation [5], with a polycystic ovary being 
widely accepted as evidence of ovarian dysfunction [6, 7]. This disease is a complex 
endocrine and metabolic syndrome in which the characteristic hyperandrogenemia 
results from dysregulation of steroidogenesis due to theca cell dysfunction [8, 9]. 
Luteinizing hormone (LH) excess is also a common feature of the disease [10] and may 
contribute to abnormal folliculogenesis and the hallmark accumulation of small antral 
follicles (2-8 mm) [11]. Hormone imbalances in androgens, estrogens, progestagens and 
LH contribute to the aberrant folliculogenesis, oligo-/anovulation, and infertility found in 
PCOS patients [12]. This syndrome also is associated with metabolic syndrome (MetS), 
which results from the interaction of obesity and insulin resistance [6, 13, 14] and which 
aggravates the hyperandrogenism of PCOS [15-17]. In fact, PCOS patients have an 11-
fold increase in the incidence of MetS compared to aged-matched controls [18]. 
Furthermore, compared with the lean PCOS cohort, obese PCOS patients with 
concomitant MetS are at increased risk for anovulation, infertility, and have lower 
conception rates [19, 20]. Currently, PCOS is classified as a heterogeneous disorder 
influenced by both heritable and non-heritable traits [21-23].  
From 2005-2008, treatment of PCOS-related infertility accounted for 
approximately $500 million per annum in the United States [24]. Moreover, within a given 
population, higher obesity rates are associated with an increased prevalence of PCOS 
[25]. As of 2008, two thirds of the American population was overweight or obese [26], 
which may indicate an increased risk for PCOS among reproductive age women in this 
  2 
country. Therefore, the public health implications and emerging economic burden of 
PCOS necessitate an appropriate, widely accessible animal model in which to examine 
heritable and non-heritable influences and molecular mechanisms of the disease, as well 
as to develop novel treatments. Although the pre-natally androgenized rhesus monkey 
model exhibits most PCOS symptoms [27], the high cost of primates and the long lag 
time to reach reproductive maturity render them impractical for large scale research [28]. 
Pigs have an estrous cycle that shares several common features with the menstrual 
cycle in women, such as the length of the overall cycle and the length of the luteal phase 
[29]. One particular breed of pig, the Ossabaw pig (OSS), has a mutation in the 
Val199IIe region of the PRKAG3 gene (the γ isoform of AMP-activated protein kinase 
(AMPK)), which causes increased accumulation of intramuscular fat and underlies their 
thrifty genotype [30, 31]. Obese OSS fed an excess calorie high fat/cholesterol/fructose 
diet have previously been used as appropriate animal models of coronary disease and 
MetS [30], obesity [32], and non-alcoholic fatty liver disease (NAFLD) [33] in humans.  
Based on this information, we hypothesize that the obese OSS is an appropriate 
model of the endocrine and paracrine pathophysiology of the obese PCOS phenotype 
with concomitant MetS. We believe that the characteristic android obesity and insulin 
resistance of the obese OSS will drive a host of reproductive and metabolic 
perturbations in this animal model which will mimic the pathophysiology of the obese 
PCOS phenotype with concomitant. Furthermore, this animal model will permit the 
interaction of genetics (pig breed) and environment (obesogenic diet) on the 
development of the obese PCOS phenotype with concomitant MetS. Our working 
scientific model is outlined in Figure 1. Chapter 2 contains an overview of the follicular 
dynamics, aberrant steroidogenesis, metabolic disturbances, and intra-follicular 
environment characteristic of PCOS, particularly in the obese phenotype. Chapter 3 
investigates the obese OSS sow as a model of the obese PCOS phenotype with 
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concomitant MetS and describes the response of this animal model to a long-term GnRH 
agonist ovarian stimulation protocol. Chapter 4 outlines our findings on metabolic 
perturbations in obese OSS gilts. Reproductive pathophysiology, including 
folliculogenesis, theca cell function, and systemic and intra-follicular endocrine 
environments, in the obese OSS gilt are discussed in Chapter 5. Lastly, Chapter 6 
summarizes the research findings and outlines the direction of future research to assess 
the utility of the obese OSS pig as an animal model for reproductive and endocrine 
pathologies.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 FOLLICULAR DYNAMICS  
2.1.1 The Hypothalamic-Pituitary-Ovarian Axis (HPOA)  
 Under normal physiology, the sensitivity of the pituitary to gonadotropin-releasing 
hormone (GnRH) changes throughout the estrous or menstrual cycle in response to 
fluctuations in E2 [34]. A threshold level of estradiol (E2) activates the hypothalamic 
surge center, resulting in increased GnRH pulse frequency and amplitude, increased LH 
synthesis and release, and the LH surge followed by ovulation and luteinization [35, 36]. 
A hypothalamus primed by E2 will experience a physiological decrease in LH frequency 
post-ovulation through the interaction of progesterone (P4) with endogenous brain opioid 
peptides [37-40]. Thus, pituitary gland response to GnRH depends on cycle phase, 
steroid milieu, and GnRH pulse amplitude and frequency [41], in addition to 
neuropeptides. Slow frequency favors follicle-stimulating hormone (FSH) secretion, and 
fast frequency favors LH secretion [42, 43] (Figure 2 A).  
Although not a diagnostic criterion, many PCOS patients, particularly lean PCOS 
patients, have an increased LH and LH:FSH ratio [44]. This defect in gonadotropin 
secretion may be caused by primary hypothalamic pathology or altered ovarian-pituitary-
hypothalamus steroid hormone feedback. Some PCOS patients have a tonic high 
frequency output of GnRH with increased amplitude and frequency of LH pulses [45] 
which may implicate an intrinsic hypothalamic defect [46-48]. On the other hand, 
centrally-mediated hyper-secretion of LH in PCOS patients may occur due to decreased 
opioid and dopaminergic tone [49-51] and altered adrenergic tone [52, 53] within the 
hypothalamus. PCOS patients require larger doses of P4 than control patients to slow 
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the frequency of GnRH pulse secretion which supports a hypothesis of decreased opioid 
and dopaminergic tone [54]. Furthermore, constant exposure to tonic E2 in anovulatory 
PCOS patients also is hypothesized to interfere with LH and FSH secretion [55]. 
Therefore, the increased LH:FSH ratio in PCOS likely arises from abnormalities in the 
E2-P4/opioid/GnRH feedback mechanism which cause high GnRH frequency, high LH 
secretion, and low to normal FSH secretion [56, 57]. In support of this theory, selective 
estrogen receptor modulators, cause increased GnRH pulse frequency, increased 
secretion of FSH, and recruitment of follicle growth in PCOS patients [58]. Sensitivity of 
the GnRH pulse generator to E2 and P4 may be influenced by androgens as treatment 
with flutamide decreases LH pulse frequency [59] and hyperandrogenism interferes with 
P4 suppression of LH pulse frequency and secretion [60, 61]. Mounting evidence 
indicates that the pathophysiology of PCOS in the hypothalamus and pituitary is 
secondary to feedback from ovarian factors, including steroid hormones [40, 62-67] 
(Figure 2 B).    
In contrast to the lean PCOS cohort, obese PCOS patients represent a 
functionally distinct population in which body mass index (BMI) may negatively correlate 
with serum LH concentrations [10, 68, 69]. The role of genetics and environmental 
influences on the obese PCOS phenotype remains to be elucidated [25]. However, 
studies in rats have shown that chronic exposure to a high fat diet results in elevated 
leptin concentrations and subsequent decreased serum E2 concentrations due to 
negative feedback of leptin on the ovary [70]. Furthermore, a reduction in LH secretion 
from the pituitary is also seen in rats fed a high fat diet that have low serum E2 
concentrations [71]. Additionally, some animal models show that LH secretion is 
suppressed by elevated insulin [72]. A recent paper by Lawson et. al. (2008) 
demonstrates that hyperinsulinemia suppresses LH secretion in obese PCOS patients 
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as well. The relationship between LH secretion and pulsatility, obesity, neuropeptides, 
and steroid hormone feedback on the HPOA remains to be fully elucidated.  
 
2.1.2 Follicular development  
Folliculogenesis is controlled by autocrine and paracrine intra-ovarian signals 
early in the process and by gonadotropins in the later stages. Anti-Müllerian hormone 
(AMH) is expressed in primary and growing follicles in humans [73] and appears to be 
essential for regulation of follicular recruitment [74, 75]. In vitro studies of human follicles 
found both inhibition [76] and initiation [77] effects of AMH on primordial follicle growth 
which indicates that AMH may have dual roles in folliculogenesis. Such results implicate 
AMH in the pathogenesis of diseases like premature ovarian failure (POF) and PCOS. 
In the primary follicle, granulosa cells proliferate, change to a cuboidal formation, 
and develop FSH receptor (FSHR) [78]. Additionally, E2 and/or P4 may play a role in the 
transition from primordial to primary follicles [79]. Mid-gestation baboon fetuses express 
estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in the germ cell cyst 
epithelium surrounding the oocytes, which suggests a direct role for E2 in primary follicle 
development in primates [80]. Development of the antral follicle, on the other hand, is 
dependent on gonadotropins. In conjunction with gonadotropins, progression from 
preantral to small antral to pre-ovulatory follicle corresponds with a shift in synthesis of 
inhibin B to inhibin A to activin A, respectively [81-83]. As the antrum forms and the 
follicle grows, ERα and aromatase function together, along with gonadotropins, to 
modulate androgen production and to effect negative feedback on the HPOA [84]. 
Furthermore, androgens may prime granulosa cells to respond to FSH through up 
regulation of FSHR [85, 86]. Selection of dominant antral follicle(s) is dependent on 
increasing serum FSH concentrations, up regulation of FSHR on the follicle, and 
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subsequent increased follicle responsiveness to FSH [87]. As the dominant follicle(s) 
develop they become less dependent on FSH and more dependent on LH [88]. In 
preparation for ovulation, the LH surge triggers expansion of cumulus cells surrounding 
the oocyte [89] as well as oocyte meiotic maturation via activation of mitogen-activated 
protein kinase (MAPK) signaling [90]. 
 The classic ovarian morphology of PCOS is the accumulation of large numbers 
of small antral follicles of 2-9 mm diameter [11]. However, increased numbers of primary 
and secondary follicles also are found in the ovaries of PCOS patients [91-93], 
suggesting defects at multiple stages of follicle development. Decreased AMH 
expression in the granulosa cells of primordial and early growing follicles of PCOS 
patients could cause increased numbers of follicles to enter the growth phase [94]. 
Moreover, androgens inhibit AMH expression, which also may promote follicle 
recruitment [95, 96]. Paradoxically, systemic serum AMH concentrations are often high 
in PCOS patients [97]. Interestingly, obese PCOS patients with hyperinsulinemia 
respond more readily than lean PCOS patients to treatment with metformin via 
decreases in systemic AMH and ovarian volume [98]. This finding suggests that AMH 
affects folliculogenesis through an insulin-mediated pathway. Furthermore, small pre-
antral follicles from PCOS patients remain viable longer in culture compared with control 
follicles which indicates there may be less follicular atresia in PCOS patients in general 
[99]. Also of significance, androgens promote expression of oocyte insulin-like growth 
factor 1 (IGF-1) and IGF-1 receptor (IGF-1R) in the primate ovary, which may initiate 
primordial follicle growth, and contribute to the large pool of antral cysts seen in PCOS 
patients [100, 101]. 
The PCOS ovary has a decreased ability to select a dominant follicle from the 
small antral follicle pool. This decreased ability may be due, in part, to the inability of 
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FSH concentrations to attain the threshold necessary for normal follicular maturation [65, 
102]. Furthermore, tonic hyper-secretion of LH in some PCOS patients may promote 
premature arrest of follicular growth in response to increased intra-follicular cyclic 
adenosine monophosphate (cAMP) concentrations and terminal follicle differentiation 
[102, 103]. Mathematical modeling of follicular dynamics in PCOS suggests that follicles 
that mature early and are hypersensitive to gonadotropins will arrest and fail to ovulate 
[104]. Moreover, some PCOS patients have increased LH pulse frequency and 
amplitude, both of which have been hypothesized to contribute to oligo-ovulation and 
subsequent oligo-menorrhea [44, 105, 106]. While anovulatory PCOS patients undergo 
active follicle growth, dominant follicle selection does not occur in these patients, which 
results in the accumulation of many arrested small antral follicles [107].    
 
2.2 HYPERANDROGENISM  
2.2.1 Relationship between androgen synthesis and follicular development 
Androgens (androstenedione, testosterone) produced by the theca interna are 
essential for normal follicular growth and for synthesis of E2 [108, 109]. The rate-limiting 
step in steroidogenesis is formation of pregnenolone (Pr) from cholesterol by side chain 
cleavage enzyme (SCC). Steroidogenesis consists of the Δ5 pathway, which converts Pr 
to dehydroepiandrosterone (DHEA) and the Δ4 pathway, which converts P4 to 
androstenedione (Δ4) [109-111] (Figure 3 A). The rate-limiting step in Δ4 formation is 
gene expression of cytochrome P450 17 (CYP17), which is dependent on LH stimulation 
in the ovary [109]. 
LH acts on the theca-interstitial-stromal cells to produce Δ4, which is used as a 
precursor for the production of E2 by aromatase in granulosa cells under the influence of 
FSH (Figure 3 A). Small antral follicles are dominated by androgen production. However, 
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once a dominant follicle is selected, there is a shift from an androgenic environment to 
one predominated by E2. In contrast, non-selected follicles contain a persistent 
androgenic environment, which results in follicular maturation arrest and eventual atresia 
[108, 112, 113]. Intra-follicular modulation of LH-induced androgen production is 
essential for proper development of the dominant follicle. Increasing LH stimulation 
results in follicular desensitization to LH via down-regulation of LH receptor (LHCGR) on 
theca cells [109, 114]. Desensitization of the theca cell to LH causes down-regulation of 
SCC, 17,20 lyase, and 17 alpha hydroxylase (17-αOH) enzymatic activity which 
ultimately results in an increased 17-hydroxyprogesterone:androgen ratio [115]. 
Androgens and estrogens inhibit LH action whereas insulin and IGF1 positively modulate 
LH activity in the follicle [109, 114] (Figure 3 A).  
 
2.2.2 Hyperandrogenism, aberrant steroidogenesis, and metabolic dysfunction in PCOS 
 Hyperandrogenism is the essence of PCOS [116]. Hyperandrogenemia in PCOS 
patients results primarily from overproduction of androgen by theca cells [114], although 
a subset of PCOS patients also experience increased androgen production from the 
adrenal gland [116]. Excessive androgen production in the ovary arises from intrinsic 
dysfunction that makes theca cells hypersensitive to direct LH stimulation and indirect 
FSH stimulation via inhibin B [116-118] (Figure 3 B). Although 3-beta-hydroxysteroid-
dehydrogenase enzyme (3βHSD) also has aberrant function, the defining feature of the 
steroidogenic abnormality in PCOS is dysregulation of CYP17, which results in 
excessive 17-hydroxyprogesterone (17OHP) synthesis in response to LH or human 
chorionic gonadotropin (hCG) [110, 116, 117]. Theca cells of PCOS patients produce 
increased amounts of testosterone (T), however, this abnormality results from increased 
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abundance of Δ4 precursors rather than aberrant 17-beta-hydroxysteroid-
dehydrogenase enzyme (17βSHD) function [119].   
PCOS patients may have low, normal, or elevated circulating serum E2 
concentrations [56, 120, 121] but often have low intra-follicular E2 concentrations [122, 
123]. However, in response to gonadotropin stimulation, granulosa cells of PCOS 
patients both in vivo [118, 124, 125] and in vitro [126] produce increased amounts of E2 
compared with controls which demonstrates normal granulosa cell functionality (Figure 3 
B). Abnormalities in aromatase function in PCOS may be caused by direct inhibition by 
intra-follicular 5α-androstane-3,17-dione (5αA) [123] or may be caused indirectly by 
relative FSH deficiency [114] or paracrine inhibition of FSH via increased local inhibin B 
concentrations ([117]; Figure 3 B).  
Theca cells from PCOS patients show increased steroidogenic enzyme activity 
resulting in increased basal and LH/insulin stimulated androgen production [9, 109, 127, 
128]. The hyperinsulinemia that occurs as a response to systemic insulin resistance in 
PCOS patients exacerbates hyperandrogenemia and associated reproductive 
pathologies [2, 12, 129-131]. Paradoxically, although tissues like muscle, adipose, and 
liver are insulin resistant in PCOS patients, the ovaries remain sensitive to insulin 
binding which allows stimulation of the androgen-producing steroidogenic pathways 
[132]. Moreover, phosphorylation of extracellular signal related kinase ½ (ERK1/2) is 
decreased by 50% in theca cells of PCOS patients and is directly associated with 
increased CYP17 expression and androgen production [133]. In fact, the severity of 
cycle irregularity [134] and hyperandrogenism [20, 135] positively correlates with 
metabolic parameters. As 50-75% of PCOS patients are insulin resistant [136], 40-50% 
are obese [137], and 33% have MetS [14], the impact of metabolic disturbances on the 
characteristic hyperandrogenemia of PCOS should not be underestimated. Furthermore, 
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hyperinsulinemia and obesity act synergistically to increase levels of androgens and 
androgens possibly increase insulin in a self-perpetuating cycle [15-17]. As current 
treatments for hyperandrogenemia in obese PCOS patients include insulin-sensitizing 
drugs and weight loss, it is evident that the interaction of metabolism and 
steroidogenesis may form the backbone of PCOS pathogenesis in obese patients [138]. 
 To assess the effect of metabolic dysfunction on the clinical manifestations of 
PCOS, patients often are classified into lean and obese phenotypes [139-141]. 
Compared with the lean PCOS cohort, obese PCOS patients are at increased risk for 
anovulation, infertility, and lower conception rates [19, 142]. Obese PCOS patients, who 
have higher serum androgen and insulin levels than lean PCOS patients, may 
experience more severe infertility due, in part, to these exacerbated endocrine 
pathologies [19]. Although PCOS patients are hyperandrogenemic, irrespective of BMI, 
obese PCOS patients have higher androgen concentrations than obese women without 
PCOS or lean PCOS women [143]. Moreover, the location of fat deposition is also a key 
element of hyperandrogenemia, as obese PCOS women with android fat distribution 
experience androgen levels elevated above those experienced by either lean PCOS 
women or obese PCOS women with peripheral fat distribution [144]. The android fat 
deposition typical of obese PCOS patients is correlated with insulin resistance and 
androgen biomarkers such as sex hormone binding globulin (SHBG) and free T [144]. 
Central adiposity works in tandem with hyperinsulinemia to compound the reproductive 
effects of the disease [14, 145]. Additionally, hyperandrogenism and oligo-ovulation with 
E2 unopposed by P4, act in concert with obesity to result in P4 resistance in the 
endometrium [146-148] and decreased pregnancy rates in obese PCOS patients [19]. 
Thus, interaction of the metabolic and endocrine abnormalities that characterize PCOS 
is essential to the perpetuation of the disease. 
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2.3 INTRA-FOLLICULAR STEROID ENVIRONMENT AND THE OOCYTE 
2.3.1 Follicular fluid steroid shifts during follicle development and oocyte maturation 
Steroid hormones work in conjunction with gonadotropins and epithelial growth 
factor (EGF) to stimulate oocyte meiotic maturation [149-151]. In mammals steroid 
hormones are not sufficient, without gonadotropins, to cause oocyte meiotic maturation 
[152-154]. However, the appropriate ratio of [155, 156] and temporal changes in [157-
159] follicular fluid steroids are essential to cellular processes involved in both 
cytoplasmic [160, 161] and meiotic maturation [162-164] as well as cumulus cell 
proliferation and differentiation [165] which are essential steps in oocyte maturation and 
directly related to oocyte developmental competence.  
In swine, E2 and, to a lesser extent, Δ4 concentration remain relatively high 
throughout the growing, pre-ovulatory period until the LH surge and germinal vesicle 
break down (GVBD) [158] (Figure 4). A physiologic block, imposed by the high systemic 
E2 and inhibin B concentrations suppresses FSH concentrations and, coupled with high 
local Δ4 and AMH, prevents small growing follicles and atretic follicles from entering the 
follicular pool such that only ovulatory size follicles remain by Day 21 of the swine cycle 
[166]. As follicular growth progresses, meiotically arrested oocytes occur most frequently 
in follicles with high steroidogenesis [167]. After the LH surge and GVBD, intra-follicular 
P4 and prostaglandin concentrations rise to affect the arrest of meiotic maturation at 
metaphase II (MII) [158, 166] (Figure 4). While high E2 concentrations drive initial oocyte 
maturation, increased P4 is essential for final oocyte maturation and cumulus cell 
proliferation and expansion in swine [165, 168].  
In humans, high E2 concentrations also are essential for initiation of oocyte 
maturation [169]. High peri-ovulatory, intra-follicular P4 concentrations are correlated 
with improved oocyte maturation [170] but a high androgen:estrogen ratio is associated 
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with degenerate oocytes [108, 158]. Similarly, healthy dominant follicles are 
characterized by an estrogenic microenvironment with an Δ4:E2 ratio < 4 [113]. A high 
androgen:E2 ratio is an indicator of follicular atresia [159, 169, 171] as androgens are 
predominant in the follicular fluid of both atretic and small, selectable follicles in primates 
[172]. The dominant follicle suppresses other follicular growth through increasing E2 
concentrations, which subsequently decreases FSH concentrations [173, 174]. After the 
LH surge, granulosa cells synthesize primarily P4 and its metabolites [175, 176], which 
results in the arrest of mitosis in granulosa cells [172, 177]. Substantial P4 
concentrations are found in follicular fluid only in follicles > 16 mm [176, 178].  
E2 [156], P4 [156, 179], and the androgen:estrogen ratio [108, 155, 169, 180] 
may be correlated with oocyte maturation and fertilization in primates. Follicular fluid 
Δ4:E2 ratio is lower in follicles containing oocytes at germinal vesicle (GV) stage than in 
follicles containing necrotic oocytes [108]. Carson et. al. (1982) found that follicular fluid 
P4 was positively correlated with successful in vitro fertilization (IVF) whereas follicular 
fluid E2 was associated with successful pregnancy [156]. Similarly, in both stimulated 
[125] and spontaneous [108, 178] cycles follicular fluid E2 concentrations are higher in 
follicles containing meiotically competent oocytes. Increased intra-follicular androgen 
concentrations, on the other hand, may adversely affect oocyte quality [181]. Lastly, it 
has been shown that pregnancy outcome after IVF is more closely associated with the 
androgen:E2 ratio rather than the absolute concentration of E2 [155].  
 
2.3.2 Potential effects of steroid environment on oocyte maturation 
When immature oocytes are removed from the follicular environment they 
undergo spontaneous meiotic maturation in vitro [182, 183] which suggests the 
existence of maturation inhibiting factor(s) within the follicular fluid [184]. However, this 
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capacity to spontaneously mature is limited to oocytes entering the final growth phase 
[162]. Despite, the propensity for spontaneous oocyte meiotic maturation in vitro, 
gonadotropins [185, 186], EGF [153, 187-189], cAMP [149, 190], nitric oxide (NO) [191-
194], and steroids [154, 195, 196] all participate in meiotic maturation (Figure 5). 
Recently, steroid hormone receptors have been found in both oocytes and cumulus 
cells, lending support for the roles of steroid hormones in oocyte maturation. In swine 
cumulus-oocyte-complexes (COCs), two isoforms of progesterone receptor (PGR) [197] 
as well as ERα and ERβ [164] have been identified in cumulus cells and ERβ [164] and 
androgen receptor (AR) [198] have been identified in oocytes (Figure 5). By comparison, 
human oocytes express ERα [199] and AR [200] in addition to cumulus cell expression 
of PGR [195].  
The role of steroid hormones in oocyte maturation has been assumed to be 
related primarily related to cumulus cell function. However, given the existence of steroid 
hormone receptors on the oocyte, steroid hormone ratios and the sequential presence of 
steroid hormones may play a prominent role in the cytoplasmic maturation of the oocyte 
[151, 201]. Sequential hormone maturation protocols mimicking in vivo follicular fluid 
conditions with increased levels of E2 and FSH for the first 10-20 hours of maturation, 
followed by a maturation media supplemented with either no hormones [202] or P4, LH 
and EGF [185] for the remainder of maturation improve cytoplasmic maturation.  
At the onset of oocyte maturation, the endoplasmic reticulum (ER) [203] and 
mitochondria [204] are located in the periphery of the cytoplasm but congregate in the 
interior regions of the cytoplasm as the oocyte matures to MII. A diffuse distribution of 
mitochondria may be important to calcium (Ca2+) changes during the final stages of 
oocyte maturation and at egg activation in response to fertilization [205]. Recently, ERβ 
has been found in the outer membrane of mitochondria [206], and G-protein coupled 
estrogen receptor 1 (GPR30) has been localized to the ER membrane [207], which 
  15 
demonstrates a potential link between E2 and intracellular Ca+2 release. Human oocytes 
exposed to an E2-enriched in vitro environment fertilize at a rate 2.8 x that of control 
oocytes. Addition of Δ4 at a concentration equal to E2 in the maturation media adversely 
affects the non-genomic intracellular increase in Ca2+ and the final stages of oocyte 
maturation, possibly due to Δ4 inhibition of estrogen receptors on the oocyte [160]. 
Therefore, maturation media or follicular fluid devoid of E2 and rich in androgens or 
cumulus cells unable to synthesize E2 may cause inhibition of intra-oocyte Ca2+ release, 
egg activation, and fertilization [160, 161].  
 
2.3.3 Intra-follicular steroid pathophysiology of PCOS 
PCOS patients commonly have a high intra-follicular androgen:estrogen ratio 
[125, 126, 208] which may contribute to poor oocyte quality [181]. Elevated intra-ovarian 
androgen concentrations significantly impair fertility in PCOS patients as evidenced by 
the restoration of ovulation in anovulatory PCOS patients upon administration of 
flutamide [209]. To date there has only been one comprehensive study of follicular fluid 
steroid profiles in un-stimulated PCOS patients [122]. In this study, PCOS patients (n= 
27) had decreased follicular fluid estrone (E1) and E2 and increased follicular fluid 
androgen (DHEA, Δ4, T, androstandione) concentrations compared with controls (n=21). 
Moreover, the ratio of androgens:estrogens was higher in PCOS patients [122]. Such 
findings support evidence of high CYP17 activity [8, 210] and low aromatase activity 
[211] previously described in PCOS patients. Low aromatase activity in PCOS patients 
may arise from inhibition by 5αA, which is found in high concentrations in the follicular 
fluid of PCOS patients [123]. One study found that a component of follicular fluid from 
PCOS patients blocks aromatase activity [212]. However, local inhibition of aromatase 
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could also occur due to increased paracrine inhibin B suppression of FSH simulation of 
granulosa cells [117] (Figure 3 B).  
PCOS patients are routinely stimulated with exogenous hormones for oocyte 
collection and IVF [121, 213].The follicular fluid from stimulated PCOS patients has 
lower P4 [125, 208, 214] and higher E2 [215] and T [125, 181] concentrations than 
follicular fluid from stimulated controls. An increased intra-follicular androgen:E2 ratio in 
stimulated PCOS patients may be associated with an increased miscarriage rate [181] 
and with decreased rates of fertilization and embryonic development [216, 217]. 
Furthermore, increased intra-follicular T concentrations may affect fertilization rate 
through decreased intracellular Ca2+ oscillations during oocyte maturation and activation 
[160, 161, 213].  
In response to stimulation, PCOS patients produce more oocytes for retrieval 
[124, 218] but experience lower fertilization rates than controls [215, 219, 220]. However, 
embryonic development in fertilized oocytes has been found to proceed normally in 
PCOS patients [221]. Such findings indicate that cytoplasmic factors may negatively 
influence fertilization in PCOS patients [218]. A meta-analysis of IVF procedures in 
PCOS patients demonstrated that despite a lower fertilization rate, PCOS patients have 
similar pregnancy and live birth rates to controls [124]. The fertilization and subsequent 
blastocyst developmental of oocytes from PCOS patients may be compromised due to 
intra-follicular E2 deficiency and an increased androgen:estrogen ratio [217, 222, 223]. 
Furthermore, microarray analysis has demonstrated that androgens may participate in 
differential gene expression in PCOS oocytes and contribute to defects in developmental 
competence [200]. The fertilization rate and developmental competence of an oocyte 
from a PCOS patient can be rescued by removal from the follicle and in vitro maturation 
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[224]. Such a finding underlines the impact of the abnormal follicular environment in 
PCOS patients on subsequent oocyte developmental competence. 
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2.4 FIGURES 
 
Figure 1. Scientific model to outline my proposed central working hypothesis that the 
obese OSS miniature pig is an appropriate model of the endocrine and paracrine 
pathophysiology of the obese PCOS phenotype with concomitant MetS.  
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Figure 2. A) Normal physiology of the hypothalamic-pituitary-ovarian axis B) 
Pathophysiology of the hypothalamic-pituitary-ovarian axis in PCOS. For simplicity, 
protein hormones secreted by the ovaries (follistatin, inhibin, activin) are not shown. 
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Figure 3. A) Two gonadotropin-two cell theory of steroidogenesis. B) Perturbations in 
two-cell steroidogenesis in the PCOS ovary. Modified from Ehrmann et. al. 1995. 
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Figure 4. Changes in in follicular fluid hormones in follicles during oocyte maturation in 
swine (Xie et. al. 1990). 
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Figure 5. Model of gonadotropin-induced oocyte meiotic maturation with demonstration 
of steroid hormone receptor distribution in the porcine oocyte and granulosa/cumulus 
cells. Modified from Zhang et. al. 2009. 
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CHAPTER 3 
INVESTIGATION OF THE OBESE OSSABAW SOW AS A MODEL FOR THE OBESE 
PHENOTYPE OF POLYCYSTIC OVARY SYNDROME WITH CONCOMITANT 
METABOLIC SYNDROME 
 
3.1 ABSTRACT 
This study characterizes the obese OSS sow as a model of the obese PCOS 
phenotype in humans and evaluates the response of this animal model to a 
superovulation protocol. Mature, cyclic, multiparous OSS sows (6-8 years old) were fed 
an excess calorie high fat/cholesterol/fructose (obese, n=4) or a control diet (control, 
n=5) for nine months prior to the study. During the four-month study, pigs remained on 
their respective diets and their reproductive and metabolic states were assessed with 
biweekly ovarian ultrasound and blood collection and weekly assessment of weights and 
measures. After such baseline measurements, they were superovulated with a long-term 
GnRH agonist protocol. Cycle length, and circulating Δ4, total testosterone (TT), P4, E2, 
FSH, LH, insulin, fructosamine, lipids, and glucose were measured. Obese pigs had 
longer estrous cycles, increased serum Δ4 concentrations, and increased luteal phase 
serum LH concentrations compared to control pigs. In the luteal phase only, obese pigs 
had more follicles in the medium, large, and cystic categories, whereas, control pigs had 
more small follicles. There were no differences in control and obese pigs in response to 
superovulation. Obese pigs were hyperglycemic, hyperinsulinemic, had elevated total 
cholesterol, triglyceride, and leptin concentrations, had abdominal adiposity, and had 
evidence of NAFLD. The obese OSS sow mimics some of the reproductive and 
metabolic abnormalities of obese PCOS patients according to the Rotterdam Diagnostic 
Criteria, indicating the potential value of this animal model for the study of PCOS. 
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3.2 INTRODUCTION 
PCOS is characterized by irregular (oligo) or absent (an) ovulation, 
hyperandrogenemia and/or polycystic ovaries [6]. Current statistics estimate that 5-12% 
of reproductive age women are afflicted with PCOS [1-3, 225, 226]. Originally defined as 
a reproductive disorder, PCOS is currently considered a complex endocrine and 
metabolic syndrome in which insulin resistance and compensatory hyperinsulinemia 
drive hyperandrogenemia and other reproductive pathologies [2, 130, 131, 227, 228]. 
PCOS patients with MetS are characterized by abdominal obesity, elevated triglycerides, 
dyslipidemia, hypertension and/or fasting hyperglycemia [6].  Approximately 40-50% of 
PCOS patients are categorized as obese [229, 230]. Compared with the lean PCOS 
cohort, obese PCOS patients have increased risk for anovulation, infertility, and have 
lower conception rates [19, 142] as well as increased risk for metabolic pathologies such 
as NAFLD, cardiovascular disease, and type 2 diabetes mellitus [136, 231, 232]. 
Moreover, obesity exacerbates the effect of hyperinsulinemia on hyperandrogenism in 
obese PCOS patients [135].  
Abnormal steroidogenesis and follicle recruitment, coupled with obesity, 
contribute to oligo-ovulation and unopposed estrogen levels in PCOS patients [12, 147]. 
Aberrant steriodogenesis in ovarian cells is one of the primary causes of dysfunctional 
follicle maturation [109].  Ovarian theca cells from PCOS patients, basally and under LH, 
insulin and IGF-1 stimulation, have increased steroidogenic enzyme activity and 
increased androgen production [9, 109, 233, 234]. Although liver, skeletal muscle, and 
fat tissues are insulin resistant in PCOS, the ovaries of PCOS patients demonstrate 
increased insulin stimulation of androgenic pathways [132]. In addition to increased 
androgen production, the ovary may have increased synthesis of E2 due to the 
bioavailability of Δ4 as an E2 precursor, and the exaggerated response of granulosa 
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cells to FSH [126]. Granulosa cells of PCOS patients inefficiently produce P4, 
sometimes resulting in an abnormal P4 to estrogen ratio [235]. Hyperandrogenism 
coupled with normal to high estrogen levels unopposed by P4, and the subsequent lack 
of an LH surge, results in abnormal folliculogenesis and anovulation [109]. PCOS 
patients who undergo superovulation are at increased risk for ovarian hyperstimulation 
syndrome (OHSS) and multiple embryo implantation [236-238]. The propensity for 
OHSS following superovulation in PCOS patients stems from increased FSH sensitivity, 
the recruitment of large numbers of follicles, and hyperestrogenemia [239]. 
Multiple animal models have been used to study PCOS [240]. Although the pre-
natally androgenized rhesus monkey model does exhibit many of the symptoms of 
human PCOS, including increased abdominal adiposity, [27, 241], the cost of primates, 
the long period required for them to reach reproductive maturity, as well as the increased 
zoonotic disease risk in these species render them inaccessible to large scale research 
[28]. Therefore, the development of an animal model that encompasses the complex 
reproductive and metabolic characteristics of the obese PCOS phenotype and is widely 
accessible would have an immense impact on the PCOS research field. Pigs are a 
valuable tool for the study of human diseases due to their anatomic, physiologic and 
biochemical similarities to humans [242].  There are considerable similarities between 
hormonal responsiveness and cycle length in humans and pigs [29]. With these 
similarities in mind, the authors sought to validate the obese OSS sow as an animal 
model for the obese PCOS phenotype with concomitant MetS. OSS have a mutation in 
the Val199IIe region of the PRKAG3 gene (the γ isoform of AMPK), which causes 
increased intramuscular fat and may underlie their thrifty genotype [30, 31]. OSS pigs, 
when fed an excess calorie high fat/cholesterol/fructose diet, naturally develop features 
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of MetS including visceral obesity, glucose intolerance, and dyslipidemia [30, 31, 243-
245].   
Our study objectives were to: 1) characterize the obese OSS sow as a model for 
the obese PCOS phenotype with concomitant MetS according to the Rotterdam 
Diagnostic Criteria and 2) evaluate the response of this animal to a typical human 
superovulation protocol. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Experimental animal procedures 
All experimental animal procedures were performed in compliance with The 
University of Illinois at Urbana-Champaign (UIUC) Institutional Animal Care and Use 
Committee (IACUC) regulations, and followed the guidelines outlined in the Guide for the 
Care and Use of Laboratory Animals [246]. Surgical ovariectomy was performed on all 
pigs under anesthesia with an IV combination of 1.1mg/kg Telazol (Fort Dodge Animal 
Health, Fort Dodge, IA), 0.27mg/kg Ketamine hydrochloride (Ketaset, Fort Dodge Animal 
Health) and 0.27mg/kg xylazine (Ben Venue Laboratories, Inc., Bedford, OH) known as 
TKX. After surgical removal of the ovaries, pigs were euthanized by an intravenous (IV) 
injection of 87 mg/kg body weight of sodium pentobarbital (390mg/ml; Fatal Plus, 
Vortech Pharmaceuticals, Dearborn, MI, USA) and other tissues were collected post-
mortem. The TKX combination was comprised of tiletamine (50mg/ml), zolazepam 
(50mg/ml), ketamine (25mg/ml) and xylazine (25mg/ml).  
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3.3.2 OSS husbandry and diet treatment 
The nine multiparous OSS sows (Sus scrofa) used in this study were aged 6-8 
years at the project onset and were obtained from the breeding colony in the 
Comparative Medicine Program of Indiana University-Purdue University Indianapolis 
(IUPUI) School of Medicine (West Lafayette, IN). All females were cyclic at the initiation 
of the study. The IUPUI breeding records show that OSS sows as old as 7 years of age 
successfully breed and wean an average of 4.2 pigs/litter. While housed at IUPUI for a 
period of 10 months prior to the start of this study, five of these pigs were fed 
approximately 2840 kilocalories (Kcal) per pig per day of a standard, control diet 
(LabDiet® Mini-Pig HF Grower 5L80, Purina Mills Inc., St. Louis, MO) and four pigs were 
fed approximately 6770 Kcal of a high fat/cholesterol/fructose diet formulated to induce 
MetS (obese diet; [245]). The obese diet was comprised of a base pelleted pig feed 
(LabDiet® Swine Diet 20% Fructose 5KA6, Purina Mills Inc.) supplemented (percentage 
by weight) with soybean oil (17.1%), cholesterol (2%), cholate (0.7%), corn oil (2.3%), 
granular fructose (8.9%) and vitamins and minerals. For four additional months 
encompassing the study period at UIUC, the control diet (Rund diet, UIUC, Urbana, IL) 
was comprised of corn (57.45%) and soy (40%) supplemented with the recommended 
daily allowances of vitamins and minerals; the obese diet was the same formulation 
which had been fed to the females at IUPUI. During the four-month study period, control 
pigs (n=5) were fed approximately 2200 Kcal of the pelleted control diet per pig per day 
and obese pigs (n=4) were fed approximately 6770 Kcal of obese diet per pig per day. 
To keep the control pigs lean, the amount of Kcal per pig per day was decreased by 
22% compared with what had been fed at IUPUI. Water was available ad libidum. Pigs 
were housed by dietary treatment group in pens of 2-4 pigs, and were exposed to a 12 
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hour light:dark cycle. At the time of euthanasia and tissue collection, all pigs in this study 
had been on their respective diets for 14 consecutive months.   
 
3.3.3 Sample collection 
To determine basal reproductive status, blood collection and ovarian ultrasound 
were performed on each pig (control, n=5; obese n=4) twice a week on fixed days during 
the first six weeks of the study. Pigs were trained to the use of a Panepinto low stress 
sling restraint system for purposes of ovarian ultrasound [247, 248]. Pigs were restrained 
manually for collection of blood from the caudal portion of the external jugular vein. 
Blood was collected for serum to assess circulating reproductive hormones, 
fructosamine and insulin and for plasma to assess blood glucose and lipid profiles. Blood 
samples were centrifuged at 1500g for 25 min and serum or plasma was removed and 
stored at -20 °C until sample analysis. Ovarian ultrasound was performed trans-rectally 
with a 7.5 mHz linear transducer (38 millimeter Linear Reproductive Transducer UST 
5541-7.5 and Aloka prosound SSD-3500SV, Aloka, Wallingford, CT) fitted with a fixed-
angle PVC handle [249]. Real time ultrasound images were DVD recorded (Sony RDR 
GX360, Sony, New York, NY) for subsequent in-depth analysis of follicular structures. 
Pigs were weighed once per week throughout the four-month study period. For 
assessment of body size, crown to rump length (between the eyes to the tail head), 
thoracic girth (in the axillary region), height (at the point of the shoulder), and abdominal 
girth (the widest point of the abdomen) also were measured once per week throughout 
the study. Pigs were checked daily for estrus by application of back pressure and 
monitoring for estrus behavior in the absence of a boar.  
3.3.4 Superovulation protocol 
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The superovulation protocol was modeled to mimic a typical long-term 
administration GnRH agonist protocol used for superovulation in human in vitro 
fertilization clinics [250]. Starting on day 10-15 of the estrous cycle (mid luteal phase), 
pigs (control, n=5; obese, n=3) received a subcutaneous (Sub-Q) 100 μg dose of the 
GnRH agonist, triptorelin acetate (Trp, ProSpec-Tany TechnoGene Ltd, Rehovot, Israel) 
twice daily until there were no ovulatory size follicles on the ovaries (range: 15-19 days 
[250]). Only three obese pigs were included in the superovulation protocol because, after 
baseline parameter assessment, one obese female had to be euthanized due to 
lameness. During the GnRH agonist down-regulation period, blood collection and 
ovarian ultrasound were conducted biweekly. Once ovarian down regulation was 
achieved as determined by no follicles visible on the ovary, two Sub-Q doses (10-20 mg 
each) of dinoprost tromethamine (PGF2α; Lutalyse, Pharmacia and Upjohn Company, 
Pfizer Inc., New York, NY) were administered 12 hours apart to induce luteolysis [251]. 
Subsequently, pigs received a total daily dose of 100 mg porcine FSH (pFSH; Folltropin-
V, Bioniche Animal Health Canada, Inc., Belleville, Canada) and 1.67 mg porcine LH 
(pLH; Lutropin-V, Bioniche Animal Health Canada, Inc.) divided equally over three Sub-
Q injections administered every eight hours. pFSH and pLH were administered for a 
period of 2-7 days, until follicles of ovulatory size (> 6.5 mm) were seen on ovarian 
ultrasound [250]. During administration of pFSH and pLH, blood samples and ultrasound 
scans were collected daily to follow hormonal and ovarian changes. Upon development 
of ovulatory size follicles, a single dose of 2500 IU of hCG (Chorulon®, Intervet Inc., 
Millsboro, DE) was administered intramuscularly (IM). The first superovulated control pig 
received an initial hCG dose of 750 IU which was not sufficient to induce ovulation; two 
days after the initial hCG administration, this control pig received an additional 2500 IU 
of hCG. All subsequent pigs in the protocol received 2500 IU of hCG, which was 
sufficient to induce ovulation. Daily blood sampling and ovarian ultrasound were 
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continued for three days post-hCG administration, or until the point of ovulation as 
detected by ovarian ultrasound. Pigs were euthanized when they had ultrasonic 
evidence of development of new ovulatory size follicles in the estrous cycle following 
superovulation.  
3.3.5 Serum hormone radioimmunoassay (RIA) 
Coat-A-Count direct P4 and Δ4 kits (Siemens Medical Solutions Diagnostics, Los 
Angeles, CA) were validated for use with pig serum. Standards were made in charcoal-
stripped domestic pig serum by adding a known amount of P4 (32-1000 pg) or Δ4 (20-
640 pg; Steraloids Inc, Newport, RI), and preparing further dilutions. For both the P4 and 
Δ4 assays, parallelism was validated for sample volumes of 50, 100, and 200 µl and 
recovery of unlabeled ligand was conducted. Once validation was completed, assays 
were run according to kit protocol, using pig serum standards. The sensitivity of the Δ4 
assay was 60 pg and this assay had an inter-assay precision of 3.0% (n=5) and an intra-
assay precision of 6.9% (n=5). The P4 assay had a sensitivity of 250 pg and an inter-
assay precision of 4.0% (n=7) and an intra-assay precision of 2.4% (n=7). Although 
rarely encountered, samples that were non-detectable were assigned the lower limit of 
detection for each respective assay. 
Serum samples for E2 and T assessment were extracted with ether and hexane-
methanol [252] prior to RIA. The ether extraction method was modified to use six ml of 
ether per sample to accommodate the large amount of serum lipids [253].  To monitor 
extraction efficiency, samples were spiked with tritiated hormone of interest (~1000 
cpm/100 μl spike/1 ml serum) prior to extraction. Hormone concentrations obtained from 
RIAs were corrected mathematically for extraction efficiency. Extraction efficiency was > 
65% for all samples. Extracted samples were reconstituted in 1% phosphate buffered 
saline-gel (PBS-gel) at the same volume of the original sample (1 ml). Coat-A-Count 
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double antibody E2 kits and single antibody TT kits (Siemens Medical Solutions 
Diagnostics) were validated for use in a buffer system. Standards were made in 1% 
PBS-gel by adding a known amount of E2 (2.5-150 pg) or T (10-1600 pg; Steraloids Inc) 
to ethanol and then preparing further dilutions. Parallelism was validated for sample 
volumes of 100, 200, 300 and 400 µl for E2 and for sample volumes of 50, 100, 200, and 
300 µl for TT. Recovery of unlabeled ligand was conducted for each assay. Once 
validation was completed, the assay was run according to kit protocol, but with 1% PBS-
gel standards. The sensitivity of the E2 assay was 2.5 pg, and this assay had an inter-
assay precision of 4.9% (n=6) and an intra-assay precision of 1.2% (n=6). The TT assay 
sensitivity was 400 pg with an inter-assay precision of 3.2% (n=3) and an intra-assay 
sensitivity of 1.9% (n=3). Samples that were non-detectable were assigned the lower 
limit of detection for each respective assay. 
Serum LH was analyzed according to a previously described double antibody 
RIA validated for pLH [254] with modifications as described. Standards (0.4-6.25 ng) 
were made with addition of purified pLH (National Hormone and Peptide Program, 
Harbor-UCLA Medical Center, Torrance, CA) to 0.1 M PBS buffer (pH 7.5) with 1% 
bovine serum albumin (BSA; Sigma Aldrich Inc., St. Louis, MO).  Aliquots of 5 µg pLH in 
5 µl distilled water were iodinated over 1 minute with 2.5 µg of chloramine-T 
(Chloramine-T hydrate 98%, Sigma Aldrich) and 0.25mCi of 125I (Iodine-125 
Radionuclide, 1mCi (37MBq), Specific Activity: ~17Ci (629GBq)/mg, 0.1M NaOH (pH 12-
14), (Reductant Free), Concentration >350mCi/ml; Perkin Elmer, Waltham, MA). The 
iodination reaction was stopped with 20 µg of sodium metabisulfite (Thermo Fisher 
Scientific, Waltham, MA) applied to the reaction vial for 5 seconds followed by 200 ul of 
0.05 M PO4  (pH 7.5) to rinse the reaction vial. The contents of the reaction vial were 
layered on resin packed column to separate free 125I from 125I-pLH. The iodinated pLH 
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(125I-pLH) solution was counted and then diluted with 1% BSA in 0.01 M PBS to create a 
stock solution of 60,000 cpm/100 µl.  Prior to use, the 125I-pLH stock solution was diluted 
to a working solution of 10,000 cpm/100 µl. Each time 125I-pLH was made a binding 
check was performed to verify adequate iodination.   
For the LH assay, primary antibody (Rabbit anti-Swine, National Hormone and 
Peptide Program) and secondary antibody (Ovine anti-Rabbit, Lampire Biological 
Laboratories, Pipersville, PA) were titered with 1% BSA in 0.1 M PBS to 1:1,200,000 and 
1:20, respectively, prior to use. The primary antibody was used at a final dilution in the 
assay of 1:4,800,000. Prior to analysis, serum samples were diluted 1:2 with 0.1M PBS 
buffer with 1% BSA to decrease potential interference of serum lipids with antibody-
antigen assay interactions. Parallelism was validated for 1:2 diluted pooled serum 
sample volumes of 100, 200, and 300 µl. Upon assay validation, all 1:2 diluted serum 
samples were run in triplicate according to the following protocol. Standards or samples 
(200 µl) and primary antibody (200 µl) were coincubated for 24 hours at 4 °C at which 
point 100 µl (~ 10,000 cpm) 125I-pLH was added to each tube, the tubes vortexed briefly, 
and the assay incubated for an additional 48 hours at 4 °C. After 72 total hours of 
incubation, 700 µl of secondary antibody mixed with 6% PEG (Sigma Aldrich) in 0.01 M 
PO4 (pH 7.5) was added to each tube, the assay was incubated for 30 minutes at 4 °C, 
the tubes were centrifuged for 20 minutes at 1800g (Eppendorf 1510 R, Hauppauge, 
NY), the supernatant was aspirated off, and the tubes were counted for 5 minutes each. 
This assay was run at an average percent binding of 29% (n=4). The sensitivity of the 
assay was 450 pg and this assay had an inter-assay precision of 4.9% (n=4) and an 
intra-assay precision of 3.6% (n=4). Samples that were non-detectable were assigned 
the lower limit of detection for this assay. 
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Serum FSH was analyzed according to a previously described double antibody 
validated for pFSH [255]. Standards (0.08-5.0 ng) were made with addition of purified 
pFSH (National Hormone and Peptide Program, Harbor-UCLA Medical Center) to 0.1 M 
PBS buffer (pH 7.5) with 1% BSA (Sigma Aldrich Inc.). Iodination of purified pFSH and 
further dilution to a working solution was conducted as described for pLH above. Primary 
antibody (Rabbit anti-Swine, National Hormone and Peptide Program) and secondary 
antibody (Ovine anti-Rabbit, Lampire Biological Laboratories) were titered with 1% BSA 
in 0.1 M PBS to 1:100,000 and 1:20, respectively, prior to use. The primary antibody was 
used at a final dilution in the assay of 1:400,000. As with the pLH, assay serum samples 
were diluted 1:2 with 0.1M PBS buffer with 1% BSA. Parallelism was validated for 1:2 
diluted pooled serum sample volumes of 100, 200, 300, 400 and 500 µl. After validation, 
samples were run in triplicate as described for the pLH assay. The FSH assay was run 
at an average binding of 34% (n=3). The sensitivity of the FSH assay was 627 pg. The 
FSH inter-assay precision was 1.9% and the intra-assay precision was 2.3%.  
 
3.3.6 Follicular dynamics  
DVD images of ovarian ultrasound were assessed on a Vizio LCD television 
(Vizio VO22LF 22-Inch 1080 pixel LCD HDTV, Vizio, Irvine, CA) using a Toshiba DVD 
player with step-through capabilities (Toshiba SD 6100 with 1080 pixel upconversion, 
Toshiba, New York, NY). Follicles and corpus luteum (CL) on each ovary were 
measured and counted individually and a conversion factor was used to determine the 
actual follicle size from the ultrasound image [256]. Follicle size categories were 
assigned as follows: <3.5 mm, small; 3.5-6.5 mm, medium; 6.5-12.5 mm, large; >12.5 
mm, cyst [257]. Although the largest follicle size was termed cyst, for a follicle to be 
classified as a cyst it must also have persisted on the ovary longer than one week. 
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3.3.7 Assessment of glucose homeostasis 
The Precision Xtra glucometer (Abbott Laboratories, Bedford, MA) was validated 
for use in the female OSS pig by the simultaneous collection of nine serum samples 
from each treatment group that were run at the University of Illinois College of Veterinary 
Medicine Diagnostic Lab (CVMVDL) and on the glucometer. A significant correlation 
(R=0.92, p<0.001) between the serum and plasma samples was achieved (SAS 9.1.3, 
SAS Inc., Cary, NC). Fasting (12-16 hour fast) plasma blood glucose (mg/dL) was 
monitored twice weekly prior to superovulation and once daily during superovulation. To 
monitor fasting blood glucose over the course of several weeks, and to rule out the 
development of diabetes in the obese pigs, serum fructosamine was assessed in each 
study pig every 4 weeks (CVMVDL). Leptin and insulin serum concentrations were 
measured bi-weekly with an RIA (Linco/Millipore Corporation, Billerica, MA). Insulin 
resistance by modified homeostatic model assessment-insulin resistance (HOMA-IR) 
was calculated by multiplying glucose and insulin [30]. 
 
3.3.8 Plasma lipids 
Monthly total plasma cholesterol (mg/dL) and triglyceride (mg/dL) concentrations 
were assayed with standard enzymatic kits (Cholesterol EZ, Triglyceride EZ, Sigma 
Aldrich). Low-density lipoprotein (LDL; mg/dL) and high-density lipoprotein (HDL; mg/dL) 
were assayed using the Cholesterol EZ kit. To determine HDL, 50 µl of a 1:1 mixture of 
MnCl2 and heparin was added to 250µl of plasma sample, precipitating out the LDL, 
which permitted assay of the supernatant for HDL using the Cholesterol EZ kit. MnCl2 
solution was a 0.002 M solution (Manganese Chloride Tetrahydrate, MP Biomedicals, 
LLC, Solon, OH) and 50,000 USP units of heparin (H 3393, Sigma-Aldrich) were 
dissolved in MilliQ water to a concentration of 4504.5 USP/ml. LDL was determined by 
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subtracting HDL and 1/5 triglycerides from total cholesterol. All plasma lipid analysis was 
conducted as previously described [30].  
 
3.3.9 Liver tissue histologic preparation 
Liver tissue was fixed in 10% buffered formalin and processed according to Lee 
[245]. Fixed pieces were embedded in paraffin wax blocks, blocks were serially 
sectioned at 5 µm thickness, and sections were transferred onto microscope slides. 
Slides were dried for 24 hours, deparaffinized with xylene, rehydrated, and stained with 
Mayer’s Haematoxalin (Sigma Aldrich) and Eosin Y Solution (Sigma Aldrich; H&E). 
Slides were examined at 400X magnification for evidence of steatosis. 
 
3.3.10 Statistical analysis 
The reproductive data were divided into two data sets: basal and superovulation. 
Response variables included in the multivariate model for both data sets were: Δ4, TT, 
P4, E2, FSH, LH, small, medium and large follicles, and cysts. Baseline estrous cycle 
data were divided into follicular and luteal phases. The percentage of estrous cycle 
length dominated by follicular and luteal phases was determined for each pig and each 
estrous cycle.  Follicular phase was defined as sample dates preceded by a decrease in 
P4 below 2 ng/ml and followed by an increase in P4 above 2 ng/ml, corresponding with 
the lack of a CL by ultrasound visualization. Luteal phase was defined as a period with 
P4 greater than 2 ng/ml with visualization of CL on ultrasound. Estrous cycle length was 
calculated from one point in time characterized by a nadir in P4 (ie, below 2 ng/ml) 
coupled with lack of CL on ultrasound and standing estrus behavior, to the next point in 
time demonstrating these three criteria. The superovulation data were subdivided by 
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percentage of stimulation completion and number of days post-hCG administration. 
Measurement parameters and metabolic data were assessed over the four-month study 
period on a weekly and biweekly schedule, respectively. For purposes of statistical 
analysis, each measurement and metabolic parameter for each pig was averaged 
monthly. The measurement and metabolic data were analyzed as one complete data 
set. Normality of data was assessed using a Levene’s test of homogeneity and Shapiro-
Wilke. Transformation of non-normal data was done logarithmically for quantitative data 
and using square root for count and ratio data. ANOVA analysis was done with PROC 
MIXED using type 3 sums of squares in SAS 9.2 (SAS, Inc.). Results from PROC 
MIXED were back transformed and the back-transformed data is presented herein as 
least square mean ± SEM. In all statistical tests, p<0.05 was the criterion for statistical 
significance.   
 
3.4 RESULTS 
3.4.1 Reproductive Parameters 
Obese pigs had a longer average estrous cycle length than control pigs (obese, 
32.2 ± 1.3 days; control, 25.2 ± 1.0 days; p=0.002), but each treatment group spent a 
similar amount of time in follicular (obese, 14.7 ± 1.1 %; control, 19.6 ± 7.0 %) and luteal 
(obese, 85.3 ± 1.1 %; control, 81.7 ± 7.6 %) phases of the cycle. Obese serum Δ4 
concentration was significantly higher than control serum Δ4 concentration in both 
follicular and luteal phases, but serum TT was not different between the two treatment 
groups (Figure 6).  
While there were no significant differences in baseline numbers of follicles 
between the two treatment groups during the follicular phase, obese pigs had 
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significantly more medium (3.5-6.5 mm), large (6.5-12.5 mm) and cystic (> 12.5 mm) 
follicles than control pigs during the luteal phase of the estrous cycle (Figure 7). Cystic 
size follicles persisted on the ovaries of control sows for 2.0 ± 0.0 days and on the 
ovaries of obese sows for 7.6 ± 6.2 days. Control pigs, on the other hand, had 
significantly more small (<3.5 mm) follicles than obese pigs during the luteal phase 
(Figure 7). There was no significant difference in the number of CL during the luteal 
phase in control (1.4 ± 0.2 CL) and obese (1.1 ± 0.2 CL; p=0.28) pigs. There was also no 
significant difference in the amount of P4 per CL in control (14.18 ± 3.52 ng/CL) and 
obese (14.52 ± 4.55 ng/CL; p=0.73) pigs. Luteal progesterone peaked at 47.4 ± 14.3 
ng/ml during the late luteal phase in control sows and at 28.9 ± 15.9 ng/ml during the 
mid luteal phase in obese sows (Figure 8). Figure 9 shows an ultrasonic image of two 
typical ovarian cysts, one on each ovary, in an obese pig. During the luteal phase, obese 
pigs also had significantly lower serum P4 concentrations but had significantly higher 
serum LH concentrations as compared with control pigs (Table 1). All other hormones 
were similar between the treatment groups during basal sampling (Table 1). 
Overall, obese and control pigs responded similarly to superovulation. During the 
superovulation period, two of three obese pigs and one of five control pigs developed 
symptoms of OHSS, including diarrhea, anorexia, and ascites. P4 concentrations rose 
and the average number of ovulatory size follicles present on the ovary fell for both 
groups on the second day post-hCG administration, demonstrating an ovulatory 
response to hCG administration. In response to superovulation, there were no significant 
differences between the two treatment groups in serum hormone concentrations or 
numbers of large follicles or cysts (Figure 10).  
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3.4.2 Metabolic Parameters 
Weight (control, 108.5 ± 3.8 kg; obese, 162.8 ± 4.9 kg; p=0.0001), thoracic girth 
(control, 123.7 ± 2.0 cm; obese, 151.2 ± 2.3 cm; p<0.0001), and abdominal girth (control, 
127.5 ± 2.5 cm; obese, 154.9 ± 2.8 cm; p=0.002) were all significantly increased in 
obese compared to control pigs (Figure 11). Height did not differ between treatment 
groups (control, 70.1 ± 1.8 cm; obese, 73.9 ± 2.3 cm; p>0.05). 
Obese pigs had fasting hyperglycemia compared with control pigs (control, 59.1 
± 2.8 mg/dL; obese, 78.7 ± 5.1 mg/dL; p=0.001; Table 2). Additionally obese pigs were 
hyperinsulinemic (control, 12.0 ± 2.3 µU/ml; obese, 23.5 ± 2.6 µU/ml; p=0.003; Table 2) 
and had significantly larger HOMA-IR scores than control pigs (control, 942.5 ± 322.9; 
obese, 1821.4 ± 365.6; p=0.024; Table 2). Despite having significant perturbations in 
both fasting glucose and insulin levels, obese pigs were not diabetic as demonstrated by 
fructosamine levels which were similar to control pigs (control, 282.73 ± 6.01 µmol/L; 
obese, 288.0 ± 6.8 µmol/L; p =0.57; Table 2). Leptin concentrations were significantly 
higher in obese pigs compared to control pigs (control, 6.6 ±1.1 ng/ml; obese, 19.8 ± 1.1 
ng/ml; p<0.0001; Table 2).   
Obese pigs had elevated total cholesterol as compared with control pigs (control, 
102.7 ± 16.7 mg/dL; obese, 215.4 ± 19.5 mg/dL; p<0.0001; Table 3). Although HDL 
(control, 32.6 ± 2.3 mg/dL; obese, 55.7 ± 6.1 mg/dL; p=0.021) and triglycerides (control, 
41.6 ± 6.1 mg/dL; obese, 87.6 ± 14.2 mg/dL; p=0.048; Table 3) concentrations were 
significantly higher in obese compared to control pigs, there was no significant difference 
between the treatment groups with respect to LDL concentrations (control, 61.7 ± 7.8 
mg/dL; obese, 87.3 ± 34.2 mg/dL; p=0.389) or LDL:HDL (control, 3.6 ± 0.4; obese, 4.8 ± 
1.2; p=0.429; Table 3).   
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Fixed H&E stained liver sections from three obese females and five control 
females were examined for evidence of steatosis. Multiple small areas of steatosis were 
observed in one out of the three obese females, whereas steatosis was not observed in 
liver sections from control females (Figure 12). 
 
3.5 DISCUSSION 
The major finding of this study is that, compared with age-matched lean controls, 
obese OSS sows were hyperandrogenemic with respect to serum Δ4 concentrations, 
had prolonged estrous cycle length, and formed persistent ovarian cysts, thereby 
meeting the Rotterdam Diagnostic Criteria for PCOS [258]. Obese OSS sows also 
developed three of the five criteria of MetS: abdominal obesity, elevated triglycerides, 
and fasting hyperglycemia [6, 231]. To our knowledge, this is the first report of PCOS 
with concomitant MetS in a large animal model. As PCOS patients afflicted with 
hyperandrogenism, oligo-menorrhea and ovarian cysts comprise 53-70% of the PCOS 
cohort [259-262] and MetS affects 33% of PCOS patients [14], our animal model will 
impact research of benefit to the majority of PCOS patients [239, 263]. In addition to 
baseline parameter similarities to human PCOS, our obese pigs had an increased 
propensity for OHSS development in response to superovulation, but had a very similar 
response to superovulation as compared to control pigs. Similarly, the response of 
obese IVF patients and lean IVF patients to superovulation are parallel [264]. These 
novel findings provide evidence that the obese OSS sow could be an appropriate animal 
model in which to study the underlying pathology and potential treatment options for the 
obese PCOS phenotype with concomitant MetS.  
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Although not significantly different due to large standard error of the mean 
(SEMs), obese OSS pigs respond to superovulation with larger Δ4 increases than 
control OSS pigs. Although obesity is linked to hyperandrogenism in both PCOS patients 
and patients with simple-obesity [265], large increases in Δ4 in superovulated obese 
pigs are suggestive of a primary ovarian abnormality in this model animal. In on-going 
studies with OSS gilts, H&E histologic sections of ovarian follicles have demonstrated 
hypertrophy of the theca layer in obese OSS and primary theca cell cultures 
demonstrate a significantly increased production of Δ4 in response to LH treatment as 
compared to control OSS, which also supports the contribution of a primary ovarian 
abnormality to increased Δ4 concentrations in this model animal.  
The lack of elevated TT concentrations in obese pigs does not fit with the 
characteristics of PCOS. The concentration of serum TT found in control and obese pigs 
is similar to previous assessments in swine [266] and humans [267], indicating accurate 
measurement of this hormone. It is possible that functional polymorphisms of 17βHSD 
[111] or homologous transcription factors for 17βHSD like Krüppel-like factor 15 (KLF15) 
[16] found in PCOS patients do not exist in swine, thereby limiting upregulated 
production of T in the porcine ovary. Furthermore, adipose tissue can convert Δ4 to T 
and vice versa via 17βHSD (AKR1C3) [268], with omental adipose favoring Δ4 
production and subcutaneous adipose favoring T production [265]. It is likely that the 
adipose tissue in our obese pigs is helping to drive the androgen milieu, perhaps 
favoring Δ4 over T production.  
Although there was little difference between the basal E2 concentrations of 
obese and control pigs and this finding is somewhat in contrast to reports of normal to 
elevated basal E2 concentrations in PCOS patients [109, 126]. Cystic follicles in human 
PCOS patients often have low follicular fluid E2 levels [269], possibly due to inhibition of 
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E2 biosynthesis [212] or direct inhibition of aromatase [122]. The steroid hormone 
concentrations of obese pigs did not correspond with the number of follicles present 
suggesting that, similar to cystic follicles in human PCOS patients, the larger sized 
follicles in our obese pigs had low E2 steroidogenesis. Despite differences in cyst size 
between human PCOS patients (2-8 mm) and our obese females (>12.5 mm), cyst basal 
physiology appears to be similar in favoring androgen excess and low to low-normal E2 
concentrations. The collection of small antral cysts in PCOS may be attributed to 
increased follicular fluid androgen concentrations [122] which inhibit AMH expression 
and promote follicle recruitment [95, 270] coupled with an inadequate FSH threshold 
necessary to facilitate dominant follicle selection and growth [65, 103] and tonic 
hypersecretion of LH which promotes follicle arrest and terminal differentiation [102]. 
Follicular selection and maturation in swine occurs similarly to humans, however, a 
cohort of dominant follicles, rather than a single follicle as in humans, with increased 
sensitivity to increasing FSH concentrations is selected [257]. Unlike humans, swine 
have a large population of small antral follicles present on the ovary throughout the 
estrous cycle [256]. In our obese pig model, the collection of post-ovulatory sized cysts 
may indicate the lack of an effective LH surge and/or an inappropriate response of the 
follicle to the LH surge. Further in vivo testing is necessary to assess the dynamics of 
the LH surge and follicular response in our model animal.  
Obese pigs had lower basal P4 concentrations during luteal phase compared 
with control pigs, but formed CL at the same rate and had no difference in the average 
P4 produced per CL compared with control pigs. In vitro studies of granulosa cells from 
PCOS patients demonstrate a markedly reduced ability of these cells to secrete P4 in 
response to a high dose of FSH and/or IGF-1 [126]. Furthermore, luteal cells from PCOS 
patients incubated in PCOS follicular fluid in vitro were slow to produce P4 [271].  It is 
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possible that the increased numbers of small antral follicles present on the ovary 
throughout the estrous cycle in control pigs are responsible for the increased luteal P4 
concentrations in our control pigs. It is important to note that although we would expect 
to find 4-5 CL on the ovaries of these sows (based on average litter size for the breed), 
we found only 1-2 CL on the ovaries of these sows. Such a finding may indicate the 
approach of reproductive senescence in our sows. Lastly, unlike findings in PCOS 
patients, it does not seem that the obese pigs experience luteal insufficiency.  
Elongated estrous cycles in the obese OSS sow are analogous to oligo-
menorrhea in PCOS patients. Although we could not determine the exact date of 
ovulation, we were able to confirm from ovarian ultrasounds that ovulation had occurred. 
Although our obese sows seem to be oligo-ovulatory based on their elongated estrous 
cycle length, we did not observe constantly elevated serum LH in the obese sows. 
Furthermore, we did not find a difference in the LH:FSH ratio between our treatment 
groups. This is perhaps due to the decreased, as opposed to absent, ovulatory cycle 
frequency in our obese pigs. Increased serum LH in obese pigs during the luteal phase 
mirrored increases in Δ4 concentrations during this time. This increase in LH and 
subsequent production of ovarian androgens corresponds with decreased P4 
concentrations. However, as LH was only measured twice weekly and LH tonic secretion 
is episodic, the LH results should be interpreted judiciously. Furthermore, low or low-
normal P4 concentrations in PCOS patients may accelerate the GnRH pulse generator, 
increase levels of LH during the luteal phase, and lead to hyperandrogenemia and 
anovulation [272]. Typical PCOS patients have increased serum LH concentrations, 
which may contribute to oligo-ovulation and subsequent oligo-menorrhea [106, 273, 
274]. However, in PCOS, BMI is negatively correlated with serum LH concentration [10, 
68, 69]. This inverse relationship between BMI and serum LH concentrations may be 
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caused by accelerated metabolism and clearance of serum LH by the liver in obese 
patients [275].   
The hyperandrogenemia in this animal model could be due to the 
hyperinsulinemia or adiposity of our obese pigs [30, 245], similar to that found in obese 
PCOS patients [276, 277]. Hyperinsulinemia and insulin resistance contribute to 
elevated levels of androgens and development of large numbers of antral follicles during 
ovarian stimulation in human patients [278]. Additionally, excessive follicle production 
coupled with hyperinsulinemia may precipitate overactive aromatization in granulosa 
cells and an elevated E2 to Δ4 ratio, rather than a strict elevation in Δ4 [279]. However, 
obesity alone is associated with increased serum androgen concentrations [143, 280]. 
Abdominal adipose tissue is particularly active in peripheral conversion of androgens to 
estrogens [143, 281-283] and T to Δ4 [265]. Some studies have found that androgen 
levels are comparable in obese and control subjects, unless the obese subject 
specifically has central deposition of adipose tissue [284]. Furthermore, obese women 
with abdominal, rather than omental, fat deposition may have increased hydroxysteroid 
dehydrogenase levels [280]. Whereas, women with omental, as opposed to 
subcutaneous, fat deposition have increased aromatase levels [285]. Several studies 
also have shown that androgen clearance rates are slower in obese as compared with 
normal women [135, 285]. Obese women with PCOS typically have higher androgen 
levels than obese women without PCOS due to adipose tissue steroid metabolism 
coupled with PCOS-related aberrant ovarian steriodogenesis [143]. Furthermore, obese 
PCOS women with android fat distribution experience androgen levels elevated above 
those experienced by either lean PCOS women or obese PCOS women with peripheral 
fat distribution [144]. It is possible that the increased Δ4 production in our obese pigs is 
the result of the combination of a primary ovarian defect, hyperinsulinemia, and the 
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intraconversion of steroid precursors by abdominal adipocytes. Similarly in obese PCOS 
patients, hyperinsulinemia and abdominal obesity are certainly major factors involved in 
hyperandrogenism and infertility [286], as significant weight loss alone can improve 
fertility and alter biochemical parameters in such patients [19].  
In addition to reproductive pathology, obese OSS sows had MetS characterized 
by abdominal obesity, fasting hyperglycemia, and elevated triglycerides. Obese pigs 
weighed more and had larger circumferences in both the thoracic and abdominal regions 
compared with control females. The height of obese and control pigs was similar; 
therefore, the increased weight of obese pigs was due to android fat deposition, rather 
than skeletal size differences. Increased abdominal girth in OSS correlates (R=0.91) 
significantly with visceral or android fat distribution [30], which is highly associated with 
type 2 diabetes mellitus and an increased risk for cardiovascular disease in humans 
[232], as well as Δ4 production [265]. Furthermore, obese PCOS patients with android 
obesity have more pronounced insulin resistance and hyperandrogenism than obese 
PCOS patients with peripheral obesity or lean PCOS patients [142, 144]. The 
hyperglycemic, hyperinsulinemic obese OSS sow appropriately models the metabolic 
abnormalities seen in the majority of PCOS patients, as 70% of such patients are 
afflicted by hyperinsulinemia, insulin resistance, and hyperglycemia [136, 287]. 
Moreover, 33% of our obese pigs showed evidence of NAFLD, which has been 
associated with 41-55% of PCOS patients [288-290] and is intimately associated with 
MetS [291]. Obese pigs had leptin concentrations three-fold higher than control pigs, 
which may indicate that obesity alone does not explain elevations in leptin elevations. 
Although obese OSS pigs did not manifest dyslipidemia as seen in 65-95% of PCOS 
patients [6, 14, 292], they did have elevated triglyceride levels and total cholesterol. 
PCOS patients with atherogenic lipid profiles tend to be obese and have more elevated 
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androgen concentrations than PCOS patients without atherogenic lipid profiles [17]. In a 
previous study in which OSS were fed an excess calorie high fat/cholesterol/fructose 
diet, young pigs (5-6 months of age at diet onset) developed dyslipidemia with high LDL 
and an increased LDL:HDL ration [30]. However, a more recent study with a slightly 
different diet formulation from Dyson et. al. (2006) also using young pigs showed an 
increase in all lipid profiles [33].  It is possible that use of younger animals or a slightly 
modified diet would permit development of dyslipidemia as seen in PCOS patients. 
Although blood pressure was not evaluated in this study, in an on-going study with a 
young group of OSS gilts (aged 1-1.25 years), hypertension has been confirmed in the 
obese pigs as compared with control pigs. Our findings of abdominal obesity, fasting 
hyperglycemia and elevated triglycerides in obese OSS sows corroborate our conclusion 
that obese OSS sows not only have symptoms of PCOS but also manifest MetS with 
evidence of insulin resistance and NAFLD.   
In conclusion, OSS sows, when fed excess high fat/cholesterol/fructose diet, 
develop many of the Rotterdam Criteria reproductive pathologies seen in obese PCOS 
patients. Obese OSS sows represent a potential animal model, applicable to large-scale 
research, in which to study treatment options for the obese phenotype of PCOS with 
concomitant MetS. 
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3.6 FIGURES AND TABLES 
 
Figure 6. Basal serum TT (ng/ml; A) and Δ4 (ng/ml; B) over one to three estrous cycles 
per pig in control (n=5) and obese (n=4) pigs. Within a given phase of the estrous cycle 
(follicular and luteal), bars with different letters indicate significantly different (p<0.003) 
serum hormone concentrations between control and obese sows.   
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Figure 7. Average number of follicles per sow in follicular (A) and luteal (B) phases of the 
estrous cycle in control (n=5) and obese (n=4) sow. Within a given follicle category, 
different letters indicate significance between control and obese sow (p<0.02).  
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Figure 8. Average number of large follicles per sow as indicated by columns on the 
figure and serum progesterone (ng/ml) as shown by the lines in the figure for a 
representative estrous cycle in control and obese sows. Within a given phase of the 
estrous cycle, columns with different letters are significantly different (p<0.05).   
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Figure 9. Transrectal ultrasound image of ovarian cysts in an obese sow (A) and large 
and medium sized follicles in a control sow (B). The ovarian cysts in the obese pig were 
A 
B 
Cysts 
Large and 
medium sized 
follicles 
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36.3 mm and 27.6 mm respectively and persisted on the ovary for approximately two 
weeks. 
Table 1. Basal estrous cycle hormones in control (n=5) and obese (n=4) sows. 
Hormone Control Obese 
 Follicular Luteal Follicular Luteal 
Estradiol (pg/ml) 51.8 ± 3.6 30.2 ± 1.9 50.8 ± 5.2 25.5 ± 2.3 
Progesterone (ng/ml) 1.2 ± 6.1 30.8 ± 3.9a 1.7 ± 9.0 16.8 ± 4.5b 
FSH (ng/ml) 2.6 ± 0.2 3.4 ± 0.1 3.1 ± 0.3 3.5 ± 0.1 
LH (ng/ml) 1.0 ± 0.1 0.9 ± 0.03c 1.0 ± 0.1 1.0 ± 0.03d 
LH:FSH ratio  0.76 ± 0.03 0.64 ± 0.01 0.69 ± 0.04 0.66 ± 0.01 
a,b p=0.04 c,d p=0.01 
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 Initial First Third Second Third Complete 1 day post 2 day post 
Control E2   10.6 ± 68.1 24.1 ± 56.3 68.6 ± 56.3 69.3 ± 56.3 67.0 ± 56.3 59.3 ± 60.0 
Obese E2 13.3 ± 112.2 29.6 ± 72.7 151.4 ± 72.7 241.2 ± 72.7 66.6 ± 72.7 47.3 ± 72.7 
Control P4 1.6 ± 0.5 1.4 ± 0.4 2.0 ± 0.6 4.1 ± 2.3 4.5 ± 3.0 10.8 ± 7.9 
Obese P4 1.7 ± 0.5 1.3 ± 0.5 2.1 ± 0.7 4.1 ± 3.0 5.2 ± 3.8 21.6 ± 10.2 
 
Figure 10. Response of follicular hormones and ovarian follicle growth to superovulation. 
Average serum Δ4 or TT (ng/ml, right Y axis) and average number of follicles per pig 
(left Y axis) in response to superovulation in control (n=5) and obese (n=3) sows. The 
table shows average E2 (pg/ml) and P4 (ng/ml) in each stage of the superovulation 
period.  
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Figure 11. Average abdominal and thoracic girths (cm; left Y axis) and weight (kg; right Y 
axis) in control (n=5) and obese (n=4) sows. Obese sows had greater abdominal (a, b; 
p=0.002) and thoracic (c,d; p<0.0001) girths than control sows and weighed more than 
control sows (e,f; p=0.0001).   
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Table 2. Assessment of glucose homeostasis in control (n=5) and obese (n=4) sows. 
 Parameter Control Obese p value 
Glucose (mg/dL) 59.1 ± 2.8 78.7 ± 5.1 0.001 
Insulin (µU/ml) 12.0 ± 2.3 23.5 ± 2.6 0.003 
HOMA-IR 942.5 ± 322.9 1821.4 ± 365.6 0.024 
Fructosamine (µmol/L) 282.7 ± 6.0 288.0 ± 6.8 0.570 
Leptin (ng/ml) 6.6 ± 1.1 19.8 ± 1.1 <0.0001 
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Table 3. Plasma lipid profiles in control (n=5) and obese (n=4) sows. 
Parameter (mg/dL) Control        Obese       p value 
Total Cholesterol  102.7 ± 16.7 215.4 ± 19.5 <0.0001 
LDL  61.7 ± 7.8 87.3 ± 34.2 0.389 
HDL   32.6 ± 2.3 55.7 ± 6.1 0.021 
Triglycerides  41.6 ± 6.1 87.6 ± 14.2 0.048 
LDL:HDL ratio 3.6 ± 0.4 4.8 ± 1.2 0.429 
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Figure 12. Representative H&E stained sections of liver tissue obtained from an obese 
(A) and a control (B) sow at 400x magnification. Black arrows indicate areas of hepatic 
steatosis in the liver of the obese sow.   
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CHAPTER 4 
METABOLIC CHARACTERISTICS OF THE OBESE OSSABAW GILT MODEL OF 
THE OBESE PHENOTYPE OF POLYCYSTIC OVARY SYNDROME WITH 
CONCOMITANT METABOLIC SYNDROME 
 
4.1 ABSTRACT 
PCOS affects approximately 5-10% of the reproductive age female population 
[1]. Its life-long disease sequelae, type 2 diabetes, cardiovascular disease (CVD), 
obesity, and MetS, create a large financial burden on the American health care system 
[2]. This study characterizes the obese OSS gilt as cost-effective large animal model of 
the metabolic pathologies associated with the obese PCOS phenotype with concomitant 
MetS. Cyclic, nulliparous OSS gilts (~6 months old) were fed an excess calorie high 
fat/cholesterol/fructose (obese, n=10) or a control diet (control, n=9) for three months 
prior to the study. During the five-month study, gilts remained on their respective diets 
and were sampled twice weekly for blood glucose, once weekly for morphometric 
measurements, and every other month for measures of glucose homeostasis and lipid 
profiles. At the conclusion of the study, gilts underwent an intravenous glucose tolerance 
test (IVGTT) to determine their level of insulin resistance and had a single blood 
pressure measurement taken. Obese OSS gilts weighed more, had android obesity, and 
a larger body size than control OSS gilts. Obese OSS gilts also were hyperglycemic, 
hypertensive, insulin resistant based on IVGTT only, had elevated serum leptin, total 
cholesterol, triglycerides, HDL, LDL, and had an increased LDL:HDL ratio as compared 
with control OSS gilts. The obese OSS gilt when fed an excess calorie high 
fat/cholesterol/fructose diet for a minimum induction period of three months manifests 
the characteristics of the obese PCOS phenotype with concomitant MetS and, therefore, 
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may represent a potential superior, cost-effective, large animal model as compared with 
the obese OSS sow for the obese phenotype of PCOS with concomitant MetS. 
 
4.2 INTRODUCTION 
 PCOS is the most common endocrine disorder in women of reproductive age [2]. 
This heterogeneous disease is tightly linked to MetS, which is characterized by 
hypertension, dyslipidemia, impaired glucose tolerance, and android obesity [231]. 
Android obesity is found in approximately 60% of PCOS patients [6] and directly 
influences the severity of insulin resistance and the development of type 2 diabetes 
mellitus and CVD [293] as well as exacerbating hyperandrogenism [142]. As up to 70% 
of PCOS patients are insulin resistant or hyperinsulinemic [294], and PCOS patients 
have an 11-fold increase in the incidence of MetS compared to aged-matched controls 
[18], the study of these sequelae and their relationship to the obese PCOS phenotype 
has held increasing importance in recent years. 
Irrespective of their BMI, PCOS patients are at risk for insulin resistance due to a 
defect in post-insulin receptor (IR) signaling in which increased serine phosphorylation 
yields decreased insulin receptor substrate 1 (IRS-1) activation and decreased glucose 
transporter type 4 (GLUT4) expression [295]. However, obesity exacerbates the 
underlying IR defects in PCOS to effect more severe defects in insulin sensitivity [20]. 
Increasingly it has become apparent that a myriad of metabolic variants exist in PCOS, 
with perturbations in the metabolism of PCOS patients strongly influenced by the 
interaction of android obesity and insulin [296]. Insulin resistance may be exacerbated in 
obese PCOS patients through increased lipolysis and the subsequent elevation in levels 
of circulating free fatty acids [297]. Recently, it also has been demonstrated that obese 
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PCOS patients have defects not only in lipid but also amino acid metabolism which may 
underlie the chronic low-grade inflammation and athrogenic tendency found in these 
women [298]. The central role of obesity in the reproductive dysfunction of PCOS 
patients cannot be overemphasized given that resumption of ovulation in anovulatory 
patients is highly correlated with early and consistent loss of intra-abdominal fat deposits 
[299]. Furthermore, the $1.77 billion per annum economic burden of treating the 
metabolic sequelae of PCOS [300] warrants research focused on the mitigation of the 
long-term health aspects of the disease.  
Given the prevalence of PCOS in the reproductive age female population, the 
heavy financial burden of this disorder on our health care system, and the lack of 
understanding about its etiology, in recent years the research community has seen 
increased interest in appropriate animal models of this syndrome [240, 301]. Pre-natally 
and post-natally androgenized animals, including various rodent models, the rhesus 
monkey, and the ewe, remain the most widespread animal models currently available for 
the study of PCOS etiology [301]. However, none of these animal models recapitulates 
the reproductive and metabolic features of the obese phenotype of PCOS with 
concomitant MetS. Furthermore, as prenatal exposure to high levels of androgens has 
not been correlated with increased risk of developing PCOS later in life [302] these 
models do not mimic the natural disease progression in humans. Our research group 
has previously examined the use of the OSS sow as a model for the metabolic and 
reproductive features of the obese phenotype of PCOS with concomitant MetS. Pigs 
share common estrous cycle features [29] and a similar LDL-dominated lipid metabolism 
with humans [303], which makes this species an attractive option for a potential animal 
model of the obese PCOS phenotype with concomitant MetS. The OSS has a mutation 
in the Val199IIe region of the PRKAG3 gene (the γ isoform of AMPK), which causes 
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increased intramuscular fat and may underlie their thrifty genotype [30, 31]. Therefore, 
when fed an excess calorie high fat/cholesterol/fructose diet, OSS naturally develop 
features of MetS including visceral obesity, glucose intolerance, and dyslipidemia [30, 
31, 243-245]. While the OSS sow holds promise as a model of some of the features of 
the obese phenotype of PCOS with concomitant Mets, the age of the animals and the 
required length of time on the obesogenic diet to induce the phenotype render this model 
extremely expensive. Therefore, the aim of this research was to validate the obese OSS 
gilt as a more cost effective animal model for the metabolic features of the obese PCOS 
phenotype with concomitant MetS.  
Our objective with this study was to demonstrate that the obese OSS gilt when 
fed an excess calorie high fat/cholesterol/fructose diet for a minimal induction period of 
three months develops android obesity and meets the Rotterdam Diagnostic Criteria for 
the development of MetS. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Experimental animal procedures 
All experimental animal procedures were performed in compliance with UIUC 
IACUC regulations, and followed the guidelines outlined in the Guide for the Care and 
Use of Laboratory Animals [246]. All anesthetic drugs and dosages used in this live 
animal study were the same as outlined under section 3.3.1. 
 
 
4.3.2 OSS husbandry and diet treatment 
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The 19 nulliparous OSS gilts (Sus scrofa) used in this study were aged 6-7 
months at the project onset and were obtained from the breeding colony in the 
Comparative Medicine Program of IUPUI School of Medicine (West Lafayette, IN). All 
females were cyclic at the initiation of the study and were sire-matched by treatment 
group. The obese diet utilized in this study was of the same composition as described 
under section 3.3.2. The control diet fed in this study was the Rund diet (UIUC). During 
the eight-month study period, control gitls (n=9) were fed approximately 2200 Kcal of the 
pelleted control diet per pig per day and obese gilts (n=10) were fed approximately 4570 
Kcal of obese diet per pig per day. A previous pilot study performed at Purdue University 
in the laboratory of Dr. Rebecca Krisher determined that it takes a minimum of 12 weeks 
on the obese diet for obese gilts to demonstrate significant differences in metabolic 
hormones and measurement parameters from control gilts. Therefore, OSS gilts were 
fed their respective diets for three months prior to the initiation of the actual study period. 
After the three-month diet induction period, gilts remained on their respective diets and 
were sampled for a five-month study period. Throughout the study water was available 
ad libidum. Gilts were housed by dietary treatment group in pens of 2-4 pigs, and were 
exposed to a 12 hour light:dark cycle. Gilts were euthanized after a total of eight months 
on diet treatment and when they had ovulatory sized follicles present on their ovaries.  
 
4.3.3 Sample Collection 
Blood collection was performed on each gilt (control, n=9; obese n=10) twice per 
week on fixed days during the five-month study. Blood collection and processing were 
conducted as described under section 3.3.3. Blood was assessed for fructosamine, 
insulin, leptin, glucose, and lipid profiles. Pigs were weighed and had morphometric 
measurements taken once per week throughout the five-month study period. As in the 
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OSS sow study, weekly measurements consisted of crown to rump length, thoracic girth, 
abdominal girth, and height. To verify that gilts were cyclic throughout the eight-month 
diet induction and study period, gilts were checked daily for estrus by application of back 
pressure and monitoring for estrus behavior in the presence of a boar. 
 
4.3.4 Assessment of glucose homeostasis 
The Precision Xtra glucometer (Abbott Laboratories) was used to measure 
fasting (12-16 hour fast) plasma glucose twice weekly in all OSS gilts. To rule out the 
development of diabetes in obese pigs, fructosamine was measured every other month 
at CVMDL. Leptin and insulin serum concentrations were measured monthly with a 
multi-species and porcine-specific RIA, respectively (Linco/Millipore Corporation, 
Billerica, MA). The leptin RIA was run at an average binding of 38.1% (n=2) and had an 
assay sensitivity of 930 pg. The inter-assay precision was 2.9% and the intra-assay 
precision was 4.5% for the leptin RIA. The insulin RIA was run at an average binding of 
43.3% (n=9) and had an assay sensitivity of 0.34 μU. The inter-assay precision was 
0.1% and the intra-assay precision was 4.0%. Insulin resistance by modified HOMA-IR 
was calculated by multiplying glucose and insulin [30]. 
 
4.3.5 Plasma lipids 
Every other month, total plasma cholesterol (mg/dL) and triglyceride (mg/dL) 
concentrations were assayed with standard enzymatic kits (Cholesterol EZ, Triglyceride 
EZ). Low-density lipoprotein (LDL; mg/dL) and high-density lipoprotein (HDL; mg/dL) 
also were assayed every other month using the Cholesterol EZ kit. Kits were utilized as 
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described under section 3.3.8. All plasma lipid analysis was conducted as previously 
described [30].  
 
4.3.6 Intravenous Glucose Tolerance Test (IVGTT) 
 The week prior to euthanasia an IVGTT was performed on gilts in the study. Only 
nine obese gilts had the IVGTT procedure, as one obese gilt died due to a cardiac 
incident prior to the end of the study. Gilts were placed in a Panepinto low stress sling 
restraint system [304] and administered isoflurane gas (Butler Schein, Dublin, OH) by 
facemask. Once gilts were in a deep anesthetic plane, they were placed in dorsal 
recumbency and a 14 gauge, 15 cm J wire IV catheter was placed percutaneously in the 
right jugular vein (Cook Medical, Bloomington, IN). A single blood pressure 
measurement was taken during the course of the IVGTT using a tail cuff 
sphygmomanometer (Critikon Dinamap 8100 / 8100T NIBP Monitor) [305]. Gilts 
recovered from isoflurane anesthesia for a minimum of two hours prior to initiation of the 
IVGTT to avoid isoflurane-induced inhibition of insulin action [305]. 
 To perform the IVGTT, gilts were placed in a Panepinto low stress sling and a 
single baseline blood sample was obtained from the IV catheter after which an IV bolus 
of 0.5 g glucose/kg was administered. Post-bolus blood samples were collected every 10 
minutes for analysis of blood glucose and serum insulin concentrations. Blood glucose 
was assessed on a YSI 2300 Stat Plus analyzer (YSI, Yellowsprings, OH) and serum 
insulin was measured on a porcine-specific RIA (Linco/Millipore).  HOMA-IR was 
calculated for each time point as described above.  
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4.3.7 Statistical analysis 
Blood glucose and morphometric measurements were assessed over the five-
month study period on a bi-weekly and weekly schedule, respectively.  Insulin, 
fructosamine, leptin and lipid profiles were assessed every other month during the study 
period. Data were analyzed as one complete set. Normality of data was assessed using 
a Levene’s test of homogeneity and Shapiro-Wilke. Transformation of non-normal data 
was done logarithmically for quantitative data and using square root for ratio data. For 
baseline data, ANOVA analysis was done with PROC MIXED using type 3 sums of 
squares in SAS 9.2 (SAS, Inc.). Analysis of the IVGTT data was done using repeated 
measures in time in PROC MIXED with an auto-regressive heterogeneous (ARH) co-
variance matrix structure. ARH was chosen as this gave the best fit statistics of all co-
variance matrix choices. Results from PROC MIXED were back transformed and the 
back-transformed data is presented herein as least square mean ± SEM. In all statistical 
tests, p<0.05 was the criterion for statistical significance.   
 
4.4 RESULTS 
4.4.1 Morphometric measurements 
 Abdominal girth (control, 97.8 ± 3.6 cm; obese, 122.4 ± 3.6 cm; p=0.0001), 
thoracic girth (control, 95.3 ± 3.3 cm; obese, 116.1 ± 3.0 cm; p=0.0003), and weight 
(control, 57.8 ± 5.4 kg; obese, 91.1± 5.1 kg; p=0.0002) were all greater in obese than 
control gilts (Figure 13). Crown rump length (control, 111.0 ± 2.3 cm; obese, 122.0 ± 2.0 
cm; p=0.02) and height (control, 58.6 ± 1.1 cm; obese, 62.7 ± 1.1 cm; p=0.02) also were 
significantly greater in the obese as opposed to control gilts.  
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4.4.2 Glucose homeostasis 
Obese gilts had fasting hyperglycemia compared with control gilts (control, 63.9 ± 
1.5 mg/dL; obese, 80.9 ± 5.1 mg/dL; p<0.0001; Table 4). However, there was no 
difference in insulin concentrations between obese and control gilts (control, 14.5 ± 1.5 
µU/ml; obese, 15.0 ± 1.4 µU/ml; p=0.8; Table 4). HOMA-IR scores also were similar 
between obese and control gilts (control, 879.0 ± 155.9; obese, 1157.4 ± 148.0; p=0.15; 
Table 4). Despite being hyperglycemic, obese gilts were not diabetic as demonstrated by 
fructosamine levels, which were similar to control (control, 254.2 ± 8.2 µmol/L; obese, 
254.8 ± 7.9 µmol/L; p =0.95; Table 4). Leptin concentrations were significantly higher in 
obese gilts compared to control gilts (control, 6.0 ±1.0 ng/ml; obese, 16.0 ± 1.0 ng/ml; 
p<0.0001; Table 4).   
 
4.4.3 Lipid profiles and blood pressure 
Obese gilts had elevated total cholesterol (control, 163.5 ± 44.2 mg/dL; obese, 
985.6 ± 41.9 mg/dL; p<0.0001; Table 5), LDL (control, 28.7 ± 42.77 mg/dL; obese, 808.7 
± 40.5 mg/dL; p<0.0001), HDL (control, 112.0 ± 4.3 mg/dL; obese, 148.8 ± 4.1 mg/dL; 
p<0.0001; Table 5), and triglycerides (control, 65.4 ± 11.1 mg/dL; obese, 99.6 ± 10.5 
mg/dL; p=0.0007) as compared with control gilts. Additionally, the LDL:HDL ratio was 
significantly increased in obese as compared with control gilts (control, 0.4 ± 0.3; obese, 
5.8 ± 0.3; p<0.0001; Table 5). Obese gilts were hypertensive compared with control gilts 
(mean arterial pressure: control, 103.0 ± 1.5 mmHg; obese, 121.5 ± 1.1 mmHg; 
p<0.0001; Figure 14). 
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4.4.4 Intravenous Glucose Tolerance Test 
Although obese gilts had significantly higher blood glucose concentrations 
compared to control gilts at all time points except for baseline and 10 minutes post 
glucose bolus, serum insulin was only significantly greater in obese gilts compared with 
control gilts at 30 minutes post glucose bolus (Figure 15). Despite these findings, 
HOMA-IR, a measure of insulin resistance, was significantly higher in obese gilts 
compared to control gilts at all time points post glucose bolus except time 0 (Figure 15). 
Therefore, we can conclude that obese gilts were glucose intolerant and insulin resistant 
based on the results of the glucose tolerance test.  
 
 4.5 DISCUSSION 
The major finding of this study is that the OSS gilt when fed an excess calorie 
high fat/cholesterol/fructose diet for a minimum induction period of three months 
develops four of the five features of MetS as described by the Rotterdam Diagnostic 
Criteria [6]: android obesity, elevated triglycerides, hypertension, and glucose 
intolerance. Our research group has demonstrated previously that the older OSS sow (6-
8 years old) develops MetS when fed an excess calorie high fat/cholesterol/fructose diet 
for a period of 14 months. However, the ability to induce MetS in a relatively short length 
of time in a young OSS gilt (6-14 months old), decreases the financial cost of this model 
while maintaining its useful metabolic features. As 50-60% of PCOS patients are obese 
[6], 65% are insulin resistant or hyperinsulinemic [230], and approximately a third are 
afflicted with MetS [14], this animal model holds wide-spread promise for the study of 
novel therapeutics targeted at the metabolic dysfunction seen in the majority of the 
PCOS patient population.   
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 Obese OSS gilts weighed more and had a larger overall body-size than control 
OSS gilts. The larger body size of obese OSS gilts is in contrast to our previous results 
in OSS sows, where obese sows only had significantly greater thoracic and abdominal 
girths compared with control sows. Furthermore, in previous studies of OSS gilts fed an 
excess calorie high fat/cholesterol/fructose diet for only 9-12 weeks, android obesity as 
measured by ultrasound, computed tomography (CT) scan, and body measurements 
increased while overall body size remained the same between obese and control gilts 
[30, 244]. In the current study, there were two control gilts with markedly smaller body 
sizes than the remaining control gilt pool, which may have skewed the morphometric 
measurements for the control gilt group. Removal of these two gilts from the 
measurement calculations does result in similar height measurements between obese 
and control gilts (control, 59.6 ± 1.1 cm, obese 62.7 ± 1.1 cm, p>0.05) but does little to 
alter the crown rump length measurements (control, 112.8 ± 2.3 cm, obese, 121.7 ± 2.0 
cm, p=0.02). As both excess and restricted calories during puberty may affect not only 
reproductive status but also size of the animal [306] and the obesogenic diet was begun 
around puberty in these gilts, the excess calories could have caused increased overall 
growth of the body frame in obese OSS gilts. Future studies in young animals should 
consider initiation of the diet at 7-8 months of age to eliminate the potential for increased 
overall body size in obese OSS gilts. Despite the overall increase in body size, obese 
OSS gilts had increased girth compared to control OSS gilts. Increased abdominal girth 
in OSS correlates (R=0.91) significantly with visceral fat distribution based on previous 
studies [30] and, therefore, indicates that the obese OSS gilt would be a good model of 
the effects of android obesity on the development of type 2 diabetes mellitus and CVD in 
humans [232] as well as the relationship between obesity, insulin resistance, and 
hyperandrogenemia [138]. 
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 Obese OSS gilts were hyperglycemic and had elevated serum leptin 
concentrations compared with control OSS gilts but did not demonstrate baseline 
elevations in serum insulin concentrations or HOMA-IR values. Despite lack of evidence 
for insulin resistance on baseline testing, obese gilts demonstrated glucose intolerance 
and insulin resistance during the IVGTT procedure. While HOMA-IR is the commonly 
utilized measurement for the assessment of insulin resistance in humans [307], definitive 
determination of insulin resistance, particularly in subclinical cases, may require the use 
of an IVGTT or an oral glucose tolerance test (OGTT) [308]. Moreover, baseline 
measurements of both glucose and insulin are not reliable indicators of insulin resistance 
in children or adolescents who often require an OGTT to definitively diagnose insulin 
resistance and/or type 2 diabetes [309]. Based on age at puberty (~ 6 months) and 
reproductive senescence (~8 years), the obese OSS gilt approximates a 15-year-old 
female adolescent. Therefore, it is possible that definitive determination of insulin 
resistance in an OSS gilt also requires the use of a glucose tolerance test. In previous 
studies from our lab, obese OSS sows had a nearly two-fold increase in baseline insulin 
concentrations compared to control OSS sows; this finding stands in stark contrast to the 
nearly identical average baseline insulin concentrations seen in obese and control OSS 
gilts. In humans, both age [310] and chronic exposure to a high fat/ cholesterol/fructose 
diet [311] are directly related to the development of insulin resistance. Therefore, it is 
difficult to compare the OSS sow and gilt animal models, which varied in age and length 
on diet. Leptin concentrations, on the other hand, were similar between obese OSS 
sows and gilts. Given that obese OSS gilts and sows both developed android obesity 
and leptin is known to be produced by adipose tissue [312], it is not surprising that these 
two variations of the obese OSS model of PCOS show similar adipokine profiles. 
However, as chronic elevations in serum insulin concentrations result in increased leptin 
production [313], one might expect the hyperinsulinemic obese OSS sows to 
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demonstrate higher leptin concentrations the obese OSS gilts. Elevated leptin 
concentrations in the follicular fluid have been associated with failed IVF cycles in 
humans [314], therefore, increased serum leptin concentrations in obese OSS gilts may 
be related to the reproductive dysfunction seen in these model animals.  
 Obese OSS gilts were hypertensive and dyslipidemic, two sequelae of the obese 
PCOS phenotype with concomitant MetS in humans that put such PCOS patients at risk 
for CVD [17]. Android obesity is an important factor in CVD development, leading to 
hypertension, altered lipoprotein metabolism, and may account for greater than 50% of 
the variation in insulin sensitivity observed in obese patients [315].  Furthermore, 
reproductive classification of PCOS patients, in particular hyperandrogenism, as it 
relates to obesity, insulin resistance, and lipid profiles, is predictive of CVD risk [316]. 
Interestingly, PCOS patients with severely abnormal lipid profiles have been found to be 
profoundly hyperandrogenemic as well [17], implicating a connection between altered 
lipid metabolism and steroidogenesis. As cholesterol is the direct precursor for the 
production of all steroid molecules, it is not surprising that increases in total cholesterol 
and LDL in PCOS patients would predispose them to hyperandrogenemia. Although the 
same diet was fed to obese OSS sows in our previous study and gilts in our current 
study, the gilts developed dyslipidemia (increased LDL and LDL:HDL ratio), whereas the 
sows did not. This finding appears to be an aberration because increasing age, in 
human women, is associated with increasing LDL and non-HDL cholesterol levels [317]. 
Another published study that utilized similarly aged gilts and fed the same obesogenic 
diet also found increased LDL and LDL:HDL ratio in the obese OSS gilts [30]. Therefore, 
it is possible that genetic variation between the OSS sows in our previous study, which 
were from the founder population on Ossabaw Island, and the OSS gilts in the current 
  69 
study, which have resulted from multigenerational inbreeding in captivity, could explain 
the differences in lipid metabolism and resulting plasma profiles.  
 In conclusion, our results demonstrate that the obese OSS gilt when fed 
an excess calorie high fat/cholesterol/fructose diet for a minimum induction period of 
three months manifests the characteristics of the obese PCOS phenotype with 
concomitant MetS. Therefore, the obese OSS gilt, when compared with the obese OSS 
sow, may represent a potential superior, cost-effective, large animal model for study of 
the metabolic perturbations associated with the obese phenotype of PCOS with 
concomitant MetS. 
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4.6 FIGURES AND TABLES 
 
Figure 13. Average abdominal and thoracic girths (cm; left Y axis) and weight (kg; right Y 
axis) in control (n=9) and obese (n=10) gilts. Obese gilts had greater abdominal (a, b; 
p=0.0001) and thoracic (c,d; p=0.0003) girths than control gilts and weighed more than 
control gilts (e,f; p=0.0002).   
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Table 4. Assessment of glucose homeostasis in control (n=9) and obese (n=10) gilts. 
Parameter Control Obese p value 
Glucose (mg/dL) 63.9 ± 1.5 80.9 ± 1.5 < 0.0001 
Insulin (µU/ml) 14.5 ± 1.5 15 ± 1.4 0.80 
Leptin (ng/ml) 6.0 ± 1.0 16.0 ± 1.0 < 0.0001 
HOMA-IR 879.0 ± 155.9 1157.4 ± 148.0 0.15 
Fructosamine (µmol/L) 254.2 ± 8.2 254.8 ± 7.9 0.95 
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Table 5. Plasma lipid profiles in control (n=9) and obese (n=10) gilts. 
Parameter (mg/dL) Control        Obese       p value 
Total Cholesterol  163.5 ± 44.2 985.6 ± 41.9 <0.0001 
LDL  28.7 ± 42.77 808.7 ± 40.5 <0.0001 
HDL   112.0 ± 4.3 148.8 ± 4.1 <0.0001 
Triglycerides  65.4 ± 11.1 99.6 ± 10.5 0.0007 
LDL:HDL ratio 0.4 ± 0.3 5.8 ± 0.3 <0.0001 
  
  73 
 
Figure 14. Systolic and diastolic blood pressure in control (n=9) and obese (n=10) gilts. 
Both blood pressure measurements were significantly different (p<0.0001) between the 
treatment groups.    
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Figure 15. Intravenous glucose tolerance test in control (n=9) and obese (n=9) gilts. 
Points on the obese gilt glucose curve marked with an * are significantly greater than 
corresponding points on the control gilt glucose curve (p<0.01). The insulin point on the 
obese gilt curve marked with a # is significantly greater than the corresponding point on 
the control gilt curve (p=0.05). As compared with control gilts, obese gilts had greater 
HOMA-IR values at all post glucose bolus points except for time 0 (p≤0.05).  
 
  
	
Time 
(mins) 
0 10 20 30 40 50 60 
 HOMA-IR 
Control 4.3 ± 1.4 183.1 ± 1.3
 
97.1 ± 1.2 80.2 ±1.3 55.0 ± 1.3 31.9 ± 1.4 26.2 ± 1.8 
Obese 5.9 ± 1.4 281.6 ± 1.3
 
238.9 ±1.2 229.0 ± 1.3 149.7 ± 1.3 91.6 ± 1.4 47.6 ± 1.8 
	
	
0 
100 
200 
300 
400 
500 
600 
700 
0 10 20 30 40 50 60 
S
e
ru
m
 I
n
s
u
lin
 (
u
U
/m
l)
 o
r 
B
lo
o
d
 G
lu
c
o
s
e
 (
m
g
/d
L
) 
Time (mins) Post Glucose Bolus 
Control Glucose Obese Glucose 
Control Insulin Obese Insulin 
* 
* 
* 
* 
* 
# 
  75 
CHAPTER 5 
REPRODUCTIVE CHARACTERISTICS OF THE OBESE OSSABAW GILT MODEL OF 
THE OBESE PHENOTYPE OF POLYCYSTIC OVARY SYNDROME WITH 
CONCOMITANT METABOLIC SYNDROME 
 
5.1 ABSTRACT 
PCOS is the most prevalent endocrine disorder in reproductive age women, 
affecting approximately 5-10% of that population [1-4]. The United States health care 
system spends approximately $4.4 billion per annum on PCOS treatment, nearly half of 
which is for infertility treatment [300]. This study characterizes the obese OSS gilt as 
cost-effective large animal model of the reproductive pathologies associated with the 
obese PCOS phenotype with concomitant MetS. Cyclic, nulliparous OSS gilts (~6 
months old) were fed an excess calorie high fat/cholesterol/fructose (obese, n=10) or a 
control diet (control, n=9) for three months prior to the study. During the five-month 
study, gilts remained on their respective diets and twice weekly had blood collection and 
ovarian ultrasound. Cycle length, and circulating Δ4, TT, dehydroepiandrosterone-sulfate 
(DHEAS), P4, E2, FSH, and LH were measured. At the conclusion of the study, gilts 
underwent an in vivo androgen challenge to determine whether they had aberrant 
androgen steroidogenesis in response to IV insulin and LH. Ovaries were harvested for 
histology, theca cell culture, follicular fluid steroid analysis, and oocyte and theca cell 
gene expression studies. Obese OSS gilts had elongated estrous cycles but spent a 
similar amount of time in follicular and luteal phases as compared with control OSS gilts. 
Obese OSS gilts were hyperandrogenemic with respect to Δ4 and DHEAS, had 
decreased LH and increased FSH concentrations, increased luteal P4, and similar E2 
concentrations compared with control OSS gilts. In both the luteal and follicular phases 
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of the estrous cycle, obese OSS gilts had ovarian cysts. Obese gilts also had increased 
numbers of medium and large sized follicles during the luteal phase of the estrous cycle 
only. The theca cells of obese OSS gilts responded to in vitro LH stimulation with 
increased production of Δ4 but there was no difference between obese and control OSS 
gilts with respect to the gene expression of primary theca cell steroidogenic enzymes. 
The follicular fluid of obese OSS gilts had an increased androgen:estrogen ratio and the 
oocytes of obese OSS gilts had down regulation of estrogen regulated genes, ESR2 and 
DNTTIP2. There was no difference between the responses of obese and control OSS 
gilts to the in vivo androgen challenge. The obese OSS gilt when fed an excess calorie 
high fat/cholesterol/fructose diet for a minimum induction period of three months 
manifests some of the reproductive characteristics of the obese PCOS phenotype with 
concomitant MetS. Further assessment of the steroidogenic roles of the adrenal and 
adipose tissue in this model animal will help to determine whether the obese OSS gilt is 
a better model of the obese PCOS phenotype with concomitant MetS or the effects of 
obesity on fertility and reproduction. 
 
5.2 INTRODUCTION 
PCOS is one of the most common female gynecologic disorders, affecting 
approximately one tenth of reproductive age women [1, 2] and costing the American 
health care system approximately $1 billion for infertility treatment per annum [300]. The 
etiology of this disease remains to be elucidated but the general consensus amongst the 
PCOS research community is that the disease arises from a complex interaction of 
inherited [318] and environmental factors [21, 319]. The Rotterdam Diagnostic Criteria 
characterize the disease by oligo/anovulation, polycystic ovaries, and/or 
hyperandrogenism [6]. However, many PCOS researchers consider hyperandrogenism 
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due to intrinsic theca cell dysfunction [8] and aberrant steroidogenesis as the basis of 
the disorder [7, 320]. PCOS also is associated with MetS that results from the interaction 
of obesity and insulin resistance [6, 13, 14] and aggravates the characteristic 
hyperandrogenism of the disorder [15-17]. Due to the heterogeneity of the disease, a 
myriad of phenotypes that include both the reproductive and metabolic pathologies have 
been described [141, 259]. Recently, many epidemiologic studies have focused on the 
biochemical and clinical differences between the lean and obese PCOS phenotypes 
[321]. 
 Although oligo/anovulation and polycystic ovaries contribute to the triad of 
reproductive pathology associated with PCOS, hyperandrogenism due to theca cell 
and/or adrenal cortex dysfunction is often considered the primary defect [116]. Theca 
cells from PCOS patients, basally and in response to LH, insulin and IGF-1, have 
increased steroidogenic enzyme activity, which yields increases in androgen production 
[9, 109, 127, 128]. The ovarian defect is indexed by selective 17OHP 
hyperresponsiveness to LH and poor dexamethasone suppression of T production [117, 
118, 322]. Although increased free androgen index (FAI) and free T are required for a 
patient to be clinically diagnosed as hyperandrogenemic [323], at the ovarian level it is 
dysregulation of 17αOH/17,20 lyase, and to a lesser extent 3βHSD, with excessive 
production of 17OHP and Δ4 that characterizes the hyperandrogenism of PCOS [116]. 
Additionally, increased systemic LH concentrations and/or hyperinsulinemia may 
exacerbate hyperandrogenemia through hyperstimulation of theca cells [109]. In a self-
perpetuating cycle, hyperinsulinemia and obesity act synergistically in PCOS patients to 
increase levels of androgens and androgens possibly increase insulin production [15-
17]. Although theca cells manifest the primary steroidogenic abnormality in PCOS, 
granulosa cells have been shown to produce decreased P4 basally and in response to 
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FSH and IGF-1 [126]. By contrast, it has also been shown that granulosa cells from 
PCOS patients have upregulated LHCGR and cytochrome P450 11A (CYP11A) 
expression, which may predispose them to early luteinization [324]. Although theca cell 
dysfunction is accepted as an underlying cause for PCOS pathology, clearly the role of 
granulosa cells in the disorder remains to be definitively defined. 
 Despite the dramatic biochemical abnormalities that underlie PCOS, many 
patients with normal menses remain undiagnosed until they encounter difficulty with 
conception [232]. While the use of assisted reproductive technologies (ART) to improve 
fertility in PCOS patients has been routinely used in the past, increasingly fertility 
researchers are investigating various follicular fluid components as predictors of IVF 
success in PCOS patients [224]. In response to ovarian stimulation, PCOS patients 
produce more oocytes for retrieval [124, 218], experience lower fertilization rates than 
controls [215, 219, 220], but boast normal embryonic development in fertilized oocytes 
[221]. Such findings indicate not only hypersensitivity to FSH stimulation but decreased 
oocyte quality possibly due to the follicular environment of PCOS. The fertilization rate 
and developmental competence of an oocyte from a PCOS patient can be rescued by 
removal from the follicle and in vitro maturation (IVM) [224]. Therefore, it is plausible that 
follicular fluid compound(s) in the PCOS patient impair oocyte maturation and 
fertilization. While follicular fluid AMH has been examined extensively as an indicator of 
oocyte quality in PCOS patients [325-327], the concentrations and relative ratios of 
follicular fluid steroid hormones also appear to play a role in oocyte quality [181]. In the 
most comprehensive evaluation of follicular fluid steroid hormone concentrations in 
PCOS patients, follicular fluid E1 and E2 were decreased and follicular fluid androgen 
(DHEA, Δ4, T, androstandione) concentrations were increased compared with controls 
(n=21) [122]. Such findings support evidence of high CYP17 activity [8, 210] and low 
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cytochrome P450 19A (CYP19A) activity [211] previously described in PCOS patients 
and underline the importance of the follicular fluid androgen:estrogen ratio. In fact, an 
increased intra-follicular androgen:estrogen ratio in stimulated PCOS patients may be 
associated with an increased miscarriage rate [181] and with decreased rates of 
fertilization and embryonic development [216, 217].  
While descriptive epidemiologic and clinical studies of PCOS patients help to 
further knowledge about the disease, the development of an appropriate animal model in 
which to examine the possible reproductive pathogenesis and test fertility-enhancing 
therapeutics would be extremely valuable. As a large percentage of the PCOS patient 
population is affected by obesity [140], MetS [6], and hyperinsulinemia [287] and these 
sequelae exacerbate the reproductive aspects of the disease, an animal model with 
these metabolic perturbations as well as the hallmark reproductive pathologies of PCOS 
would be extremely useful. Our research group has previously examined the use of the 
obese OSS sow as a model for the metabolic and reproductive features of the obese 
phenotype of PCOS with concomitant MetS. The OSS, has a mutation in the Val199IIe 
region of the PRKAG3 gene (the γ isoform of AMPK), which interferes with insulin 
signaling and results in increased intra-abdominal and subcutaneous adipose 
accumulation when fed an excess calorie high fat/cholesterol/fructose diet [30, 31]. The 
strengths of this particular animal as a model for the obese phenotype of PCOS with 
concomitant MetS lie in the interaction of genetics (thrifty phenotype breed) and 
environment (obesogenic diet). Such an animal model for PCOS would help elucidate 
the complex interaction between obesity, hyperinsulinemia, and hyperandrogenism in 
the context of heritable and non-heritable factors. While the obese OSS sow holds 
promise as a model of some of the features of the obese phenotype of PCOS with 
concomitant Mets, the age of the animals and the required length of time on the 
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obesogenic diet to induce the phenotype render this model extremely expensive. 
Therefore, the aim of this research was to validate the obese OSS gilt as a more cost 
effective animal model for the reproductive features of the obese PCOS phenotype with 
concomitant MetS.  
Our objective with this study was to demonstrate that the obese OSS gilt, when 
fed an excess calorie high fat/cholesterol/fructose diet for a minimal induction period of 
three months, meets the Rotterdam Diagnostic Criteria for the development of PCOS. 
 
5.3 MATERIALS AND METHODS 
5.3.1 Experimental animal procedures, husbandry, and diet treatment 
All experimental animal procedures were performed in compliance with UIUC 
IACUC regulations, and followed the guidelines outlined in the Guide for the Care and 
Use of Laboratory Animals [246]. All anesthetic drugs and dosages as well as tissue 
harvest techniques used in the research associated with this chapter were the same as 
those outlined under section 3.3.1. The animals utilized in this portion of the dissertation 
were the same animals utilized in Chapter 4. Please refer to section 4.3.2 for details on 
dietary induction of phenotype and husbandry of these animals.  
 
5.3.2 Sample collection 
To determine reproductive status, blood collection and ovarian ultrasound were 
performed on each gilt (control, n=9; obese n=10) twice per week on fixed days during 
the five-month study. Pigs were trained to the use of a Panepinto low stress sling 
restraint system for purposes of ovarian ultrasound [247, 248]. Blood collection and 
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processing and ovarian ultrasound were conducted as described under section 3.3.3. 
Blood was collected for serum to assess circulating reproductive hormones. Throughout 
the dietary induction phase and study period (eight months), pigs were checked daily for 
estrus by application of back pressure and monitoring for estrus behavior in the 
presence of a boar. Estrus was used in conjunction with serum hormone and ovarian 
ultrasound data to determine cycle length (see statistical analysis). 
 
5.3.3 Serum hormone RIA 
  The following hormones were assessed bi-weekly in the serum throughout the 
five-month study: E2, P4, Δ4, TT, DHEAS, FSH, and LH. All assays were validated for 
use with swine serum or extracted samples using parallelism and recovery of cold 
ligand. All samples that were non-detectable were assigned the lower limit of detection 
for each assay. To remove lipids from serum samples prior to RIA, serum for the 
assessment of all steroid hormones except DHEAS was extracted with the ether and 
hexane-methanol procedure described in section 3.3.5 above. To monitor extraction 
efficiency, samples were spiked with tritiated hormone of interest (~1000 cpm/100 μl 
spike/1 ml serum) prior to extraction. Hormone concentrations obtained from RIAs were 
corrected mathematically for extraction efficiency. Extraction efficiency was > 65% for all 
samples. After extraction, all samples were reconstituted in 1% PBS-gel to the volume of 
the original serum sample (1 ml). All steroids with the exception of DHEAS were 
assessed using Coat-A-Count kits (Siemens Medical Solutions Diagnostics). For the 
assessment of E2 (2.5-150pg), P4 (32-1000 pg), Δ4 (20-640pg), and TT (10-1600 pg) 
standards were made by adding a known amount of the respective steroid hormone to 
1% PBS-gel and then preparing further dilutions. The sensitivity of the E2 assay was 4.5 
pg, and this assay had an inter-assay precision of 2.0% and an intra-assay precision of 
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1.0%. The E2 assay was run at an average binding of 47.9% (n=6). The TT assay 
sensitivity was 230 pg with an inter-assay precision of 5.0% and an intra-assay 
sensitivity of 2.1%. The TT assay was run at an average binding of 32.3% (n=4). The 
sensitivity of the Δ4 assay was 360 pg and this assay had an inter-assay precision of 
3.2% and an intra-assay precision of 0.9%. The Δ4 assay was run at an average binding 
of 33.3% (n=7). The P4 assay had a sensitivity of 50 pg and an inter-assay precision of 
1.8% and an intra-assay precision of 1.8%. The P4 assay was run at an average binding 
of 56.5% (n=5).  
DHEAS was assessed using a Beckman Coulter double antibody kit (DHEA-S-7 
RIA, DSL 2700, Beckman Coulter Inc, Brea, CA). Standards (25-2500 pg) were made by 
adding a known amount of DHEAS to PBS-gel and then making further dilutions in 
charcoal stripped pig serum. The DHEAS assay was run at an average binding of 26.8% 
(n=7) and had an assay sensitivity of 1055 pg. The inter-assay precision was 5.0% and 
the intra-assay precision was 1.5%.  
Serum LH and FSH were analyzed according to previously described double 
antibody RIAs validated for pLH [254] and pFSH [255], respectively, with modifications 
as described in section 3.3.5 above. The LH assay was run at an average percent 
binding of 24.8% (n=7). The sensitivity of the assay was 240 pg and this assay had an 
inter-assay precision of 12.9% and an intra-assay precision of 5.3%. The FSH assay 
was run at an average binding of 31.9% (n=7). The sensitivity of the FSH assay was 393 
pg. The FSH inter-assay precision was 1.7% and the intra-assay precision was 4.2%.  
 
5.3.4 Follicular dynamics  
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DVD images of ovarian ultrasound were assessed as previously described in 
section 3.3.6. Follicle size categories were assigned as follows: <3.5 mm, small; 3.5-6.5 
mm, medium; 6.5-12.5 mm, large; >12.5 mm, cyst [257]. Although the largest follicle size 
was termed cyst, for a follicle to be classified as a cyst it must also have persisted on the 
ovary longer than one week. 
 
5.3.5 Ovarian histology 
 Gilts were euthanized and ovaries harvested when there were ovulatory sized 
follicles (6.5-12.5 mm) present. At tissue harvest, a subset of gilts (n=3 from each 
treatment group) had one of their ovaries placed in Dietrichs fixative for ovarian histology 
while the other ovary was reserved for theca cell culture. After 48-72 hours in Dietrichs 
fixative, ovaries were transferred to 70% ethanol until processing. Fixed ovaries were 
sectioned transversely into 1 mm thick slices and then were embedded in paraffin wax 
blocks. Paraffin blocks were serially sectioned at 7µm thickness, and sections were 
transferred onto microscope slides. Slides were dried for 24 hours, deparaffinized with 
xylene, rehydrated, and stained with Mayer’s Haematoxalin (Sigma Aldrich) and Eosin Y 
Solution (Sigma Aldrich; H&E). Ovulatory sized follicles were examined at 100-400x for 
evidence of normal architecture of the theca and granulosa cell layers.  
 
5.3.6 Primary theca cell culture 
 Only gilts (control, n=4; obese, n=6) not included in the in vivo androgen 
challenge test had primary theca cell culture. After harvest from the abdominal cavity, 
ovaries not designated for histologic techniques were placed immediately in cold (~ 4 
°C) HEPES (Sigma Aldrich) containing 0.1% BSA (w/v), 1.0 mM glutamine and 1x 
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essential and non-essential amino acids (MP Biomedicals, Costa Mesa, CA) until 
processing. To isolate theca cells for cell culture, ovulatory sized follicles were isolated 
from the ovary and bisected. Follicular fluid from bisected follicles was frozen at -20 °C 
for assessment of steroid hormone concentrations and oocytes were isolated from the 
follicular fluid and processed as described below. Theca interna and granulosa cell 
layers were stripped from the theca externa and connective tissue with forceps. 
Granulosa cell layers were mechanically stripped from the theca interna by repeatedly 
running the theca interna through a pair of closed forceps. Theca interna tissue pieces 
were allowed to settle by gravity in PBS on ice after which they were digested in a 15 ml 
conical with 0.1% collagenase XI (Sigma Aldrich) on a rotating rocker for 15-20 minutes. 
Digested theca cells were washed 3x in DMEM/F12 media with phenol red 
supplemented with 15% charcoal stripped fetal bovine serum (FBS; Charcoal/Dextran 
Treated Fetal Calf Serum, Thermo Scientific Hyclone, Logan, UT), 1x vitamins (v/v; 100x 
Vitamins MEM modification, MP Biomedicals), and 1% penicillin-streptomycin-
actinomycin (v/v; PSA, MP Biomedicals). The theca cell pellet was resuspended in 
approximately 1 ml of the above media and the cell suspension was counted with 0.2% 
(v/v) trypan blue solution (Trypan Blue Solution 0.4%, Gibco, Invitrogen™, Carlsbad, 
CA) and a hemocytometer. Large pieces of theca cells were run through a 22 gauge 
needle and 3 ml syringe multiple times to further pulverize prior to plating. Theca cells 
were plated at a density of 250,000 live cells per a well in 750 μl of the above-described 
cell culture media in 24 well tissue-culture treated Costar plates (Costar 3524, Costar®, 
Cambridge, MA). Cells were cultured in humidified 95% air and 5% CO2 at 37 °C and 
were allowed to reach at least 60% confluence prior to treatment. 
 Once cells reached at least 60% confluence, three wells per treatment were 
washed with the treatment media two times followed by application of 750 μl of treatment 
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media per well. Treatment media included: control, LH (10 ng/ml), insulin (100 ng/ml), 
and LH + insulin (10 ng/ml and 100 ng/ml). All treatment media consisted of DMEM/F12 
with 1% PSA, 1x vitamins and 1% SSS (v/v; Synthetic Serum Substitute, Irvine 
Scientific, Santa Ana, CA). Insulin from porcine pancreas (Sigma Aldrich) and pLH 
(Sioux Biochemical, Inc, Sioux Center, IA) were used to make the treatment media. After 
48 hours, treatment media was removed from each well and frozen at -20 ° C in a 1.5 ml 
tube for future steroid hormone analysis. Theca cells were trypsinized with 200 μl of 
0.25% trypsin with EDTA (v/v 0.5% Trypsin EDTA, Invitrogen, Carlsbad, CA), counted 
using a 0.2% trypan blue solution and a hemocytometer, and frozen at -80 °C in 300 μl β 
mercaptoethanol RLT lysis buffer (Qiagen Inc, Valencia, CA) for subsequent PCR 
analysis. 
 
5.3.7 Follicular fluid hormone assessment 
Follicular fluid from gilts (control, n=4; obese, n=6) not included in the in vivo 
androgen challenge test cohort was analyzed. Follicular fluid collected from bisected 
ovulatory sized follicles (8-13 follicles) was assessed for the following steroid hormones: 
E2, P4, Δ4, TT and 17OHP. To remove lipids and proteins, the follicular fluid (500 μl) 
was extracted with 3 ml of diethyl ether (Sigma Aldrich). Extraction efficiency was 
monitored as described under section 5.3.3 and was > 90% for all follicular fluid 
extractions. Extracted samples were reconstituted in 1% PBS-gel to the volume of the 
original follicular fluid sample (500 μl). All steroid hormone assays (Coat-A-Count, 
Siemens Medical Solutions Diagnostics) were validated for a buffer-based system by 
parallelism and recovery of cold ligand. Samples for assessment of E2 were diluted 
1:800 to 1:600 prior to analysis. Samples for assessment of 17OHP were diluted 1:20 
prior to analysis. Samples for assessment of Δ4 were run at 3% of the kit-required 
  86 
sample volume per tube, whereas samples for the assessment of TT were run at 6% of 
the kit-required sample volume per tube. Samples for assessment of P4 were run at 2% 
of the kit-required sample volume per tube.  
 
5.3.8 Theca cell and oocyte gene expression 
 Theca cells and oocytes from gilts (control, n=4; obese, n=6) not included in the 
in vivo androgen challenge cohort were assessed for gene expression. Total RNA was 
extracted from primary theca cell aliquots of 100,000 cells using the RNeasy Mini Kit 
(Qiagen Inc) and an on-column DNase treatment (RNase-free DNase Set, Qiagen Inc). 
Total RNA was quantified on the Nanodrop (Nanodrop 3300, Thermo Scientific, 
Wilmington, DE). RNA samples with an OD260/OD280 ratio > 1.8 on the Nanodrop had 
adequate RNA extraction and were bioanalyzed for RNA quality (Agilent Bioanalyzer, 
Functional Genomics Unit, Keck Center, UIUC). Total RNA was reverse transcribed to 
cDNA (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems Inc, 
Carlsbad, CA), diluted 1:5 with RNAse –free water, followed by qRT-PCR (TaqMan 
Gene Expression Assay, Applied Biosystems Inc) on a 7900HT Fast Real-Time PCR 
System (Applied Biosystems Inc) to determine relative fold differences in the following 
mRNA expression: 3-beta-hydroxysteroid dehydrogenase 1 (HSD3β1), 17-beta-
hydroxysteroid dehydrogenase 4 (HSD17β4),  and 17-alpha-hydroxylase/17,20 lyase 
(CYP17A1). Our endogenous gene, 18s ribosomal RNA (RN18S1), was tested between 
control and obese tissues and demonstrated similar replication amongst the treatment 
groups.  Applied Biosystems TaqMan Gene Expression Assay for HSD3β1: 
Ss03391752_m1; Applied Biosystems TaqMan Gene Expression Assay for HSD17β4: 
Ss03394675_m1; Applied Biosystems TaqMan Gene Expression Assay for CYP17A1: 
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Ss03394947_m1; Applied Biosystems TaqMan Gene Expression Assay for RN18S1: 
Hs99999901_s1. 
 Oocytes harvested from ovulatory sized follicles were washed 3x in cold 0.1% 
polyvinyl alcohol (PVA) in PBS (v/v) and then snap frozen (-80 ° C) in 3 μl volume in 
groups of 8-9 oocytes per pig per tube for gene expression analysis. Total RNA was 
extracted (PicoPure® RNA Isolation Kit, Applied Biosystems Inc) with an on-column 
DNase treatment (RNase-free DNase Set, Qiagen Inc), reverse transcribed to cDNA 
(High Capacity cDNA Reverse Transcription Kit, Applied Biosystems Inc), diluted 1:3 
with RNAse –free water, followed by qRT-PCR (TaqMan Gene Expression Assay, 
Applied Biosystems Inc or Sybr Green Quanti-fast, Qiagen Inc) to determine relative fold 
differences in the following mRNA expression: estrogen receptor beta (ESR2), estrogen 
receptor binding protein (DNTTIP2), androgen receptor (AR), progesterone receptor 
(PGR). 18s ribosomal RNA (RN18S1) served as the endogenous control gene for the 
oocyte qRT-PCR.  
Due to the small amount of starting material, we were unable to quantify the total 
RNA we put into the cDNA reaction, and, thus, how much we were loading into the qRT-
CPR assay. Therefore, we created a bulk pig cDNA pool (liver, oocyte, theca), which we 
quantified on the Nanodrop (Nanodrop 3300, Thermo Scientific) and from which serial 
dilutions (1:10, 1:50, 1:100, 1:500, 1:1000) were made to create a relative standard 
curve for each gene. The efficiency of the standard curve for each gene was between 88 
and 106%. qRT-PCR was performed on ESR2, DNTTIP2, PGR using Taqman Gene 
Expression Assays: Applied Biosystems Taqman Gene Expression Assay for ESR2: 
Ss03391479_m1; Applied Biosystems Taqman Gene Expression Assay for DNTTIP2: 
Ss03391479_m1; Applied Biosystems Taqman Gene Expression Assay for PGR: 
Ss03374439_m1. qRT-PCR for AR was performed using Sybr Green (Sybr Green 
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Quanti-fast, Qiagen Inc) on a MasterCycler Realplex2 (Eppendorf North America, Inc, 
Westbury, NY). Primers were tested on pooled theca cells or oocytes and primer 
specificity was determined by melt curve analysis and gel electrophoresis. AR primer 
sequences: forward 5’-AGACGCGGAGACAGGATAAA-3, reverse 5’-
CCTGGGTTCTGGATCACTTC-3’. RN18S1 primer sequences: forward 5’-
CGGCTACCACATCCAAGGAA-3’, reverse 5’-CTCAATCGGATCCTCGTTAAAGG-3’.  
 
5.3.9 In vivo androgen challenge  
 Eight gilts (control=4, obese=4) underwent the in vivo androgen challenge the 
day of euthanasia. Bilateral percutaneous IV catheters were placed as described in 
section 4.3.6. Prior to initiation of the challenge, a baseline blood sample was collected.  
For the first hour of the challenge, IV insulin (Humulin-R, Eli Lilly, Indianapolis, IN) was 
administered at a rate of 0.4 U/kg/hr as a continuous rate infusion (CRI). For the second 
hour of the challenge, IV insulin continued to be administered and was coupled with IV 
pLH (Sioux Biochemical Inc) administered at a rate of 1 μg/kg/hr as a CRI. To maintain 
blood glucose levels within normal physiologic levels (50-100 mg/dL), IV 20% dextrose 
was administered continuously throughout the challenge. During the challenge, blood 
was collected every 10 minutes for assessment of steroid hormones and blood glucose. 
After the two-hour challenge period, blood was collected every 30 minutes until 
euthanasia two hours post-challenge.  
 
 
 
5.3.10 Statistical analysis 
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Response variables included in the multivariate model were: Δ4, TT, DHEAS, P4, 
E2, FSH, LH, small, medium and large follicles, and cysts. Two consecutive complete 
estrous cycles were analyzed per gilt. Baseline estrous cycle data were divided into 
follicular and luteal phases. The percentage of estrous cycle length dominated by 
follicular and luteal phases was determined for each gilt and each estrous cycle. 
Follicular phase was defined as sample dates preceded by a decrease in P4 below 2 
ng/ml and followed by an increase in P4 above 2 ng/ml, corresponding with the lack of a 
CL by ultrasound visualization. Luteal phase was defined as a period with P4 greater 
than 2 ng/ml with visualization of CL on ultrasound. Estrous cycle length was calculated 
from one point in time characterized by a nadir in P4 (ie, below 2 ng/ml) coupled with 
lack of CL on ultrasound and standing estrus behavior, to the next point in time 
demonstrating these three criteria. Normality of data was assessed using a Levene’s test 
of homogeneity and Shapiro-Wilke. Transformation of non-normal data was done 
logarithmically for quantitative data and using square root for count and ratio data. 
ANOVA analysis was done for reproductive response variables, follicular fluid hormone, 
and cell culture media data with PROC MIXED using type 3 sums of squares in SAS 9.2 
(SAS, Inc.). Repeated measures in time analysis with an auto-regressive (AR1) co-
variance structure in PROC MIXED using type 3 sums of squares was used to analyze 
the in vivo androgen challenge test data. Results from PROC MIXED were back 
transformed and the back-transformed data is presented herein as least square mean ± 
SEM.  
 For theca qRT-PCR results, the mRNA abundance of target genes was 
normalized to an endogenous control gene, RN18S1, for sample-to-sample 
comparisons. The relative fold induction of each gene was then compared between 
obese and control gilts using the ΔCT method. For oocyte qRT-PCR, the mRNA 
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abundance of target genes was normalized to an endogenous control gene, RN18S1, 
using a bulk pig cDNA standard curve. Oocyte data was analyzed using the relative 
expression software tool, REST 2009 version 2.0.13 [328], with RN18S1 set as the 
reference gene. Expression ratios were generated using PCR efficiencies of the target 
and reference genes and the ΔCT values of the control and obese samples [329]. In all 
statistical tests, p<0.05 was the criterion for statistical significance.   
 
5.4 RESULTS 
5.4.1 Baseline reproductive status 
Obese gilts had a longer average estrous cycle length than control gilts (obese, 
22.2 ± 1.1 days; control, 19.6 ± 1.1 days; p=0.0001), but each treatment group spent a 
similar amount of time in follicular (obese, 20.6 ± 7.4 %; control, 20.8 ± 4.9 %; p=0.5) 
and luteal (obese, 79.9 ± 8.0 %; control, 79.2 ± 6.9 %; p=0.4) phases of the cycle. 
Obese serum Δ4 concentration (0.35 ± 0.3 ng/ml) was significantly higher than control 
serum Δ4 concentration (0.28 ± 0.03 ng/ml; p=0.005) in the luteal phase only (Figure 
16). Serum TT was not different between the two treatment groups (Figure 16). Obese 
gilts had higher DHEAS concentrations during both the follicular (control, 0.17 ± 0.10 
ng/ml; obese, 0.23 ± 0.01 ng/ml; p<0.0001) and luteal (control, 0.19 ± 0.01 ng/ml; obese, 
0.25 ± 0.01 ng/ml; p<0.0001) phases of the estrous cycle (Figure 16).  
Obese gilts had significantly more cystic follicles (>12.5 mm) than control gilts in 
both the follicular and luteal phases of the estrous cycle (Figure 17). Cystic size follicles 
persisted on the ovaries of control gilts for 3.0 ± 1.4 days and on the ovaries of obese 
gilts for 3.8 ± 6.2 days. Obese gilts had significantly more medium (3.5-6.5 mm) and 
large (6.5-12.5mm) follicles than control pigs during the luteal phase of the estrous cycle 
only (Figure 17 B). There was no significant difference in the number of CL during the 
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luteal phase in control (4.7 ± 0.4 CL) and obese (4.6 ± 0.3 CL; p=0.9) gilts. Control gilts 
had higher serum LH concentrations than obese gilts, while obese gilts had higher 
serum FSH concentrations than control gilts (Table 6). Therefore, control gilts also had a 
significantly higher LH:FSH ratio than obese gilts (Table 6). Obese gilts had significantly 
higher serum P4 concentrations during the luteal phase only. There was no difference in 
serum E2 concentrations the two treatment groups (Table 6).  
 
5.4.2 Ovarian histology 
 All ovaries from control gilts demonstrated normal theca interna and granulosa 
cell layers in all large follicles visualized within the ovarian cortex. One of the three 
obese gilts had an ovary with hypertrophy of both the theca interna and granulosa cell 
layers in two out of four large follicles visualized within the ovarian cortex (Figure 18).  
 
5.4.3 Follicular fluid steroid hormone concentrations, theca cell androgen production, 
and theca and oocyte gene expression 
 While there was no difference in the absolute concentrations of Δ4 (control, 50.0 
± 43.6 ng/ml; obese 97.9 ± 39.0 ng/ml; p=0.4), TT (control, 18.5 ± 9.5 ng/ml; obese, 23.7 
± 8.5 ng/ml; p=0.7), E2 (control, 72.8 ± 25.2 ng/ml; obese 31.3 ± 22.5 ng/ml; p=0.4), P4 
(control, 35.9 ± 17.8 ng/ml; obese, 60.7 ± 16.0; p=0.3), and 17OHP (control, 15.3 ± 6.8 
ng/ml; obese, 20.8 ± 6.1 ng/ml; p=0.6) in the follicular fluid of control and obese gilts, 
obese gilts had significantly greater Δ4:E2 and TT:E2 ratios than control gilts (Figure 
19). 
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 Primary theca cells from obese gilts produced increased amounts of Δ4 in cell 
culture in response to treatment with LH (10 ng/ml) as compared with control gilts 
(control, 0.15 ± 0.03 ng/ml; obese, 0.25 ± 0.03 ng/ml, p=0.03; Figure 20). All other theca 
cell culture treatments yielded similar Δ4 production amounts between the control and 
obese gilts.  
 Primary theca cells did not demonstrate differential gene expression with respect 
to HSD3B1, HSD17B4 or CYP17A1 between control and obese gilts (Figure 21 A). 
ESR2 and DNTTIP2 were significantly down regulated in obese as opposed to control 
gilt oocytes, whereas PGR and AR were similarly expressed in oocytes from the two 
treatment groups (Figure 21 B). 
5.4.4 In vivo androgen challenge  
 Control and obese gilts produced similar amounts of serum Δ4 in response to 
insulin infusion alone and insulin + LH infusion. However, two hours after the completion 
of the in vivo androgen challenge, the average Δ4 production by obese gilts became 
significantly greater than the production by control gilts (Figure 22).  
 
5.5 DISCUSSION 
The major finding of this study is that, compared with age-matched lean controls, 
obese OSS gilts fed an excess calorie high fat/cholesterol/fructose diet for a minimum 
induction period of three months were hyperandrogenemic with respect to serum Δ4 and 
DHEAS concentrations, had prolonged estrous cycle length, and formed persistent 
ovarian cysts, thereby meeting the Rotterdam Diagnostic Criteria for PCOS [258]. Our 
research group has demonstrated previously that the older OSS sow (6-8 years old) 
develops similar reproductive pathologies when fed an excess calorie high 
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fat/cholesterol/fructose diet for a period of 14 months. However, the ability to induce 
many of the reproductive pathologic features of PCOS in a relatively short length of time 
in a young OSS gilt (6-14 months old) decreases the financial cost of this model while 
maintaining its usefulness. The OSS gilt model also has been shown by our research 
group to develop android obesity and MetS. Therefore, the obese OSS gilt may be a 
cost efficient large animal model of the obese phenotype of PCOS with concomitant 
MetS in which to study some of the effects of obesity and metabolic disturbances on 
hyperandrogenism and reproductive dysfunction.  
Although obese OSS gilts had elongated estrous cycles, which are analogous to 
oligo-menorrhea in human PCOS patients, they did not demonstrate elongation of either 
the follicular or luteal phases. This stands in stark contrast to PCOS patients whose 
oligo-menorrhea is due to persistent small antral cysts (2-9 mm) and elongation of the 
follicular phase of the menstrual cycle [6]. Interestingly, our obese OSS gilts did develop 
cysts, however, unlike human PCOS, these cysts were post-ovulatory size (>12.5 mm) 
and could be found in the presence of formed CL tissue. The fact that the cysts in obese 
OSS gilts were post-ovulatory size and coupled with large numbers of medium and large 
sized follicles during the luteal phase indicates a dysfunction in folliculogenesis during 
the later stages of recruitment and dominant follicle selection and persisting past the 
point of normal dominant follicle ovulation [257]. Furthermore, in contrast to what is seen 
in obese PCOS patients who have low to normal serum LH and normal serum FSH 
concentrations [69], the obese OSS gilts in this study had low serum LH and high serum 
FSH concentrations. The fact that obese OSS gilts had low LH indicates that obesity and 
insulin resistance may have caused suppression of LH secretion [72], as is seen in some 
obese PCOS patients. Moreover, such low LH concentrations in obese OSS gilts may 
cause the development of post-ovulatory size cysts due to an inability to mount an LH 
  94 
surge necessary for ovulation [330]. The elevation in FSH concentrations, however, 
does not fit with any PCOS phenotype. Increases in FSH concentrations normally occur 
around the time of menopause in humans [331]. Furthermore, pathologic increases in 
FSH concentrations in humans may occur during the reproductive disease states of 
incipient ovarian failure (IOF; normal menses), transitional ovarian failure (TOF; oligo-
menorrhea), premature ovarian failure (POF; oligo/amenorrhea) [332-334]. Given that 
obese OSS gilts had irregular estrous cycle lengths and elevated FSH concentrations 
and normal E2 concentrations, they could have a reproductive pathology similar to TOF. 
However, the production of copious numbers of selectable and dominant follicles and 
cysts and the remaining hormone milieu does not mimic TOF. Nonetheless, elevated 
FSH concentrations in obese OSS gilts may be related to the increased recruitment of 
medium sized follicles during the luteal phase of the cycle.  
Interestingly, steroids produced in the adrenal cortex like cortisol have been 
linked to post-ovulatory size ovarian cyst production in pigs [335] and obesity is known to 
increase the production of cortisol via stimulatory effects of hyperinsulinemia [336]. 
Furthermore, menstrual cycle abnormalities are a common occurrence in 
hypercortisolemic conditions like Cushing’s disease [337]. In an on-going study with the 
OSS gilt, preliminary assessment indicates that the obese OSS gilt has elevated cortisol 
concentrations compared with the control OSS gilt (data not shown). Therefore, the role 
of the adrenal gland in the reproductive abnormalities of this model animal should not be 
underestimated. In fact, the two androgens found in excess in the obese OSS gilt, Δ4 
and DHEAS, are produced by theca cells and the adrenal cortex in pigs [338] and 
humans [116]. One may argue that since TT was not increased in obese OSS gilts and 
this androgen is considered the hallmark of hyperandrogenism in PCOS patients [323], 
obese OSS gilts are not hyperandrogenemic. However, intrinsic theca cell dysfunction of 
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CYP17 [8, 9] and a parallel defect in the adrenal cortex [339] comprise the primary 
steroidogenesis defects in PCOS. Therefore, increased serum Δ4 and DHEAS 
concentrations are supportive of theca and/or adrenal cortex dysfunction in obese OSS 
gilts. TT concentrations were similar between the obese OSS gilts and sows, indicating 
accurate hormone measurement and similar physiology between our model animals. 
Given that visceral adipose tissue is known to interconvert steroids, favoring Δ4 
production from T [265], and that our obese OSS gilts had android obesity, it is possible 
the adipose tissue in obese OSS gilts contributes to the hyperandrogenism, favoring Δ4 
over T production. However, adipose tissue alone cannot be responsible for the steroid 
milieu in obese OSS gilts, because there is no evidence of increased aromatization [340] 
nor of general androgen sequestration due to fatty acid esters present in the tissue 
[341].  
Ovarian theca and granulosa cell hypertrophy in a single obese OSS gilt is a 
somewhat similar histopathologic finding to what is seen in PCOS patients. Although the 
typical PCOS ovary has attenuated granulosa cell layers and/or luteinized theca within 
the follicles, a subset of follicles may maintain granulosa cell layers [342]. Evidence of 
architectural abnormalities within several follicles of an obese OSS gilt is suggestive of 
possible cellular dysfunction. Interestingly, we received conflicting results with respect to 
basal and stimulated theca cell function, possibly due to individual pig differences 
overshadowing overall treatment differences due to the small sample size. We did not 
find any differences between control and obese OSS gilts in gene expression of 
steroidogenic enyzmes in primary theca cells. However, we did find increased 
production of Δ4 in primary theca cell cultures of obese OSS gilts in response to in vitro 
stimulation with LH. Such findings support a translational, rather than transcriptional, 
mechanism by which CYP17 causes increased steroid production. Methods to assess 
  96 
protein concentrations of CYP17 and 3βHSD in theca cells (ie, IHC or western blot) 
would help elucidate the mechanism of Δ4 hypersecretion in our model animal. We 
hypothesize that the lack of difference in in vitro Δ4 production in obese versus control 
OSS gilts in response to insulin based treatments is due to down-regulation or lack of IR 
function on theca cells of obese OSS gilts. We know from our previous studies that 
obese OSS gilts are insulin resistant; therefore, supplementation of theca cells in culture 
with insulin-based treatments is unlikely to cause a response. Such a finding is in 
contrast to PCOS patients who are systemically insulin resistant but retain insulin 
sensitivity within the ovary [132]. We see a similar response with the in vivo androgen 
challenge, as there is no difference in serum Δ4 concentrations during IV 
supplementation with insulin or insulin+ LH. However, after removal of exogenous insulin 
and LH, we see a “Somogyi effect” or rebound of serum Δ4 concentrations in obese 
OSS gilts. It is likely that the dosing of the insulin, the LH, or both was too high for the 
short-term administration period of the test. Therefore, down-regulation of IR and 
LHCGR on the theca cells may have occurred which would have muted subsequent 
steroid release. In our previous study with obese OSS sows, the results from our 
superovulation protocol suggested that the obese OSS ovary is hyperresponsive to LH 
in an FSH-primed environment. For future in vivo studies of theca cell function in obese 
versus control OSS gilts, it is recommended to perform an hCG or gonadotropin 
stimulation test on an unprimed ovary as is the gold standard for clinical diagnosis of 
subtle PCOS cases [118].  
Despite indications that theca cells of obese OSS gilts aberrantly produce Δ4 
both basally and in response to LH stimulation, the follicular fluid of obese OSS gilts 
does not demonstrate absolute increases in androgens or androgen precursors. 
However, relative to estrogens, androgens are increased in the follicular fluid of the 
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obese OSS gilt, which may indicate CYP19A dysfunction [343]. Interestingly, although 
absolute E2 is not decreased in the follicular fluid of obese OSS gilts, the gene 
expression of two estrogen-regulated genes, ERS2 and DNTTIP2, is down regulated on 
oocytes from obese OSS gilts. PCOS patients also have increased androgen:estrogen 
ratio in their follicular fluid [122] and may show decreased aromatase activity [123, 211, 
212]. Although ERα and estrogen receptor binding protein (ERBP) are found in human 
oocytes [199], the exact mechanism of their action in the oocyte is unknown nor have 
these proteins been examined in the context of oocyte quality in PCOS. Future studies 
that examine oocyte quality and competence in obese versus control OSS gilts as they 
relate to the intra-follicular environment and oocyte gene expression may elucidate the 
roles of steroid hormones and their receptors.  
In conclusion, our results demonstrate that the obese OSS gilt when fed an 
excess calorie high fat/cholesterol/fructose diet for a minimum induction period of three 
months manifests some of the characteristics of the obese PCOS phenotype with 
concomitant MetS. Therefore, the obese OSS gilt, when compared with the obese OSS 
sow, may represent a potential superior, cost-effective, large animal model for study of 
the obese phenotype of PCOS with concomitant MetS. Future studies that focus on both 
in vivo and in vitro stimulation of theca cells and the adrenal cortex will further 
characterize the sources of excessive androgen production in this model animal.  
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5.6 FIGURES AND TABLES 
 
 
Figure 16. Serum androgens in control (n=9) and obese (n=10) gilts. Within a given 
phase of the estrous cycle (follicular and luteal) and androgen hormone, bars with 
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different letters indicate significantly different (p<0.005) serum hormone concentrations 
between control and obese gilts.   
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Figure 17. Average number of follicles per gilt in follicular (A) and luteal (B) phases of the 
estrous cycle in control (n=9) and obese (n=10) gilts. Within a given follicle category, 
different letters indicate significance between control and obese gilts (p<0.03). 
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Table 6. Basal estrous cycle hormones in control (n=9) and obese (n=10) gilts.  
Hormone  Control Obese 
 Follicular Luteal Follicular Luteal 
Estradiol (pg/ml) 18.3 ± 1.8 7.8 ± 1.0 14.0 ± 1.8 7.8 ± 0.8 
Progesterone (ng/ml) 1.3 ± 2.0 11.0 ± 0.9a 1.4 ± 1.9 16.1 ± 0.8b 
FSH (ng/ml) 1.7 ± 0.1c 2.2 ± 0.1e 2.2 ± 0.1d 2.6 ± 0.1f 
LH (ng/ml) 5.2 ± 0.6g 3.2 ± 0.4i 3.3 ± 0.6h 2.2 ± 0.1j 
LH:FSH ratio  3.1 ± 0.4k 1.5 ± 0.3m 1.5 ± 0.4l 0.85 ± 0.1n 
a,b p=0.002; c,dp=0.005; e,fp<0.0001; g,hp=0.02; I,j p=0.01; k,lp=0.02; m,np=0.02.   
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Figure 18. Representative H&E stained sections of ovarian tissue from a control (A) and 
an obese (B) gilt at 100x magnification (400x magnification in inset). The obese gilt has 
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hypertrophy of the granulosa and theca interna layer with vacuolation in the theca 
interna.  
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Δ4:E2 0.4 ± 0.3a 1.2 ± 0.2b 
T:E2 (CYP19) 0.2 ± 0.1c 0.4 ± 0.1d 
17OHP:Δ4 
(17,20 lyase) 
0.6 ± 0.3 0.4 ± 0.3 
P4:17OHP4 
(17αOH) 
2.5 ± 0.7 3.6 ± 0.6 
  
Figure 19. Follicular fluid steroid hormone concentrations and ratios in control (n=4) and 
obese (n=5) gilts. Within a given ratio, different letters indicate significance between 
control and obese gilts (p=0.03). Steroidogenic enzymes in parentheses after a given 
ratio indicate the enzyme function the ratio approximates.  
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Figure 20. Primary theca cell Δ4 production in response to control, LH (10 ng/ml), insulin 
(100 ng/ml) or LH + insulin (10 ng/ml + 100 ng/ml) in control (n=4) and obese (n=5) gilts. 
Bars with different letters are significantly different (p=0.03).   
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Figure 21. Theca (A) and oocyte (B) gene expression in control (n=4) and obese (n=5) 
gilts. For a given gene, bars with different letters show significantly different relative fold 
induction (p<0.04).   
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Figure 22. Production of serum Δ4 in response to an in vivo androgen challenge with IV 
insulin (0.4 U/kg/hr) and pLH (1 μg/kg/hr) in control (n=4) and obese (n=4) gilts. Two 
hours after the challenge was complete serum Δ4 concentrations rose dramatically in 
obese gilts to become significantly greater than serum Δ4 concentrations in control gilts 
(*p=0.05).  
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Polycystic ovary syndrome is the most common endocrine disorder of 
reproductive age women. As the etiology of this disorder is not fully understood and as 
animal models of human disease are useful to determine disease pathogenesis, recent 
research efforts have focused on the development of an appropriate animal model for 
PCOS.  In this Ph.D. dissertation I sought to validate the obese OSS pig as an animal 
model for the obese phenotype of PCOS with concomitant MetS. The main findings of 
this work are that when OSS pigs were fed an excess calorie high 
fat/cholesterol/fructose diet: 1) both OSS sows and gilts developed android obesity and 
metabolic perturbations, including but not limited to dyslipidemia, hypertension and 
glucose intolerance, that met the Rotterdam Diagnostic Criteria for MetS; 2) both OSS 
sows and gilts developed persistent post-ovulatory size ovarian cysts; 3) both OSS sows 
(Δ4 only) and gilts (Δ4 and DHEAS) became hyperandrogenemic; 4) both OSS sows 
and gilts developed protracted estrous cycle length; 5) both OSS sows and gilts 
developed increased numbers of medium and large size follicles during the luteal phase 
of the estrous cycle; 6) OSS sows had increased LH and decreased P4 serum 
concentrations; 6) OSS gilts had decreased LH and increased FSH serum 
concentrations; 7) OSS sows responded to a long-term GnRH agonist superovulation 
protocol similarly to OSS sows on a control diet; 8) the theca cells of OSS gilts did not 
demonstrate basal differences in the gene expression of steroidogenic enzymes but did 
respond to in vitro LH stimulation with increased production of Δ4; 9) OSS gilts had an 
increased androgen:estrogen ratio in the follicular fluid and demonstrated down 
regulation of estrogen controlled genes on oocytes; 10) OSS gilts responded to an in 
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vivo androgen challenge similarly to OSS gilts on a control diet. Based on these findings 
I have revised my working model of the whole-animal physiology of the obese OSS pig 
(Figure 22).  
The research in this dissertation demonstrates that the obese OSS pig is an 
excellent model animal for obesity and MetS in humans. Furthermore, the obese OSS 
sow and gilt possess at least some of the reproductive features of the obese phenotype 
of PCOS. However, based on the findings of my Ph.D. research, neither of these animal 
models completely recapitulates all of the reproductive features, nor the exact 
pathophysiology, of the obese phenotype of PCOS with concomitant MetS. Moreover, 
both sows and gilts demonstrated some differences in the response of their reproductive 
physiology to the obesogenic diet. As there were several sources of variation between 
the two animal models, including age (6-14 months old versus 6-8 years old), genetics 
(generational captive inbred versus wild-caught), and length of time on diet (8 months 
versus 14 months), it is difficult to pinpoint an exact reason for the differential response 
in the reproductive parameters. It is possible that the obese OSS sow and/or gilt may be 
better suited as models of the effects of obesity on reproductive and endocrine 
physiology. The bulk of this Ph.D. research was descriptive in nature and generated data 
primarily related to the systemic environment of the obese OSS pig. Therefore, many of 
the black, solid arrows linking different research findings on the revised working model 
are hypotheses rather than concrete facts (Figure 22).  
The obese OSS gilt model is more cost effective, requires a shorter time frame to 
generate data, shares many of the core reproductive features with the obese OSS sow 
model, and generated a small amount of data on the molecular mechanisms and intra-
follicular environment. Therefore, future research designed to further define the utility of 
this animal model should focus on the obese OSS gilt. Besides the metabolic features, 
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the hyperandrogenemic environment remains a strong suit of this animal model. 
Although several findings in the obese OSS gilt model  (ie, increased theca cell 
production of Δ4 in response to LH in vitro, increased androgen:estrogen ratio in the 
follicular fluid, abnormal granulosa and theca cell appearance on histology) indicate a 
role for the ovary in the generation of androgens, the contribution of other androgen-
producing tissues cannot be excluded. Therefore, research in the obese OSS gilt that 
examines the role of the adrenal gland and adipose tissue as well as expands on 
knowledge of the theca, granulosa, and oocyte physiology will further characterize the 
molecular mechanisms underlying the hyperandrogenemia in this animal model. 
Additionally, incorporation of a lean genetic control into future research studies of the 
obese OSS gilt would be helpful in discerning the roles of genetics and diet in the model.  
 In on-going research as a part of my NIH K01 grant I plan to address the 
following questions and complete the following in vivo and in vitro experiments in 
Yorkshire-cross gilts (n=6), lean OSS gilts (n=6), and obese OSS gilts (n=6). Such 
experiments are designed primarily to discern the roles of the ovary, adrenal, and 
adipose tissue in the generation of increased concentrations of androgens (Δ4 and 
DHEAS) in the obese OSS gilt model. The addition of a lean control pig breed will help 
determine if the OSS gilt has a genetic predisposition to the increased production of 
androgens by one or all of the above-mentioned tissues. Animals will be 6 months old at 
the start of the study. Pigs will be allowed to undergo 2-3 cycles prior to initiation of the 
“diet induction” period of the study (4 months). Pigs will be assessed for baseline 
parameters over 1-2 estrous cycles prior to the following experiments being conducted. 
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1) Do obese OSS gilts have elevated serum 17OHP and Δ4 in response to hCG ovarian 
stimulation? 
The goal of this experiment is to assess ovarian steroidogenic response to hCG 
administration in our animals. After 5-6 estrous cycles, pigs will be ultrasounded daily 
starting eight days prior to the next estimated estrus. Three days before estrus, when CL 
regression and small follicles (<3.5 mm) are present on ovarian ultrasound (US), animals 
will be fasted 12 hours, placed in a low stress restraint sling, anesthetized with isoflurane 
via face mask, and an IV catheter will be passed into the external jugular vein. We will 
allow 24-48 hours between catheter placement and stimulation procedures. Prior to 
stimulation testing, a morning baseline blood sample will be collected after which 7.5 
µg/kg dexamethasone will be administered IM to suppress coincident adrenal secretion 
of 17OHP and Δ4. Six hours later a blood sample will be collected and 2000 IU of hCG 
(Pregnyl®, Schering-Plough) will be administered IV [344]. Blood will be sampled at the 
following intervals post-hCG administration: 12, 24, 36, 48, and 72 hours [118]. 
Dexamethasone will be administered every 12 hours throughout the stimulation. To track 
ovarian changes, pigs will be trans-rectally ultrasounded every 12 hours for 4 days post-
hCG administration. Serum collected during hCG stimulation will be assessed for 
17OHP, DHEA, DHEAS, Δ4, cortisol, E2, P4. 
 
2) Do obese OSS gilts have elevated serum DHEA post-ACTH stimulation? 
The goal of this experiment is to assess adrenal steroidogenic response to ACTH 
stimulation. We will conduct US and place IV catheters as outlined above. Based on US, 
when there are medium size follicles and no CL present on the ovary, we will begin 
ACTH stimulation. A morning baseline blood sample will be collected from the jugular 
catheter after which 5 µg/kg dexamethasone will be administered IM to uniformly provide 
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low baseline secretion of adrenocortical steroids, which will enhance ascertainment of 
the response to exogenous ACTH. Six hours after dexamethasone administration, a 
blood sample will be collected and 1 µg/kg of ACTH (human ACTH(1-24); Neosystem) 
dissolved in 5ml sterile 0.9% saline will be injected via the jugular catheter [345]. Blood 
will be sampled at the following intervals post-ACTH administration: 15, 30, 60, 90, 120, 
180 minutes. Serum collected pre and post ACTH stimulation will be assessed for 
17OHP, Δ4, cortisol, and DHEA.  
 
3) Do obese OSS gilt theca cells demonstrate underlying elevations of CYP17 and 
HSD3β1 in vitro in response to LH and/or insulin? 
 The goal of this experiment is to assess theca cell functional response to LH ± 
insulin in vitro. Such results will build upon data generated from theca cell culture 
conducted as a part of my Ph.D. research. Follicular phase ovaries with medium size 
follicles (to prevent luteinization in culture) will be collected from the live pigs in our 
study. Aliquots of 500,000 primary theca cells per animal will be frozen at -80 °C for 
qRT-PCR analysis. Remaining theca cells will be plated at a density of 105 cells/well 
[346] in DMEM/F12 with 10% charcoal stripped FBS (CSFBS) and penicillin-
streptomycin-actinomycin (PSA) in 12-well plates,  allowed to reach 60% confluence, 
and then treated with either control (no treatment), LH (10 ng/ml), insulin (100ng/ml), LH 
(10 ng/ml) + insulin (100 ng/ml) for 48 hours [346, 347]. Cell culture medium will be 
assessed for 17OHP and Δ4. Cultured and freshly isolated theca cells will be analyzed 
for gene expression of HSD3β1 and CYP17. Follicular fluid will be assessed for TT, Δ4, 
and 17OHP.  
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4) Do adrenal explants of obese OSS gilts demonstrate underlying elevations of 
CYP17, HSD3Β1 and SULT2A1 in vitro in response to ACTH? 
The goal of this experiment is to assess baseline steroid production and 
steroidogenesis in adrenocortical explants in vitro in response to ACTH. One adrenal 
harvested at euthanasia from each pig will be finely minced immediately and kept on ice 
in serum free DMEM/F12 media until further prompt processing [348, 349]. The other 
adrenal gland collected at euthanasia will be bisected with half placed into 10% neutral 
buffered formalin for IHC and half frozen for qRT-PCR. Cultures of explanted adrenal 
minces supplemented with 10 µM Pr (Steraloids), will be cultured for 24 hours then will 
be treated for 24 hours with: control (no treatment); 10-6 M ACTH; 10-7 M ACTH; and 10-9 
M ACTH [350-352]. Cell culture media will be assessed for 17OHP, cortisol, DHEA, and 
DHEAS [349, 352]. Adrenal cortex gene regulation will be assessed from primary, non-
cultured adrenal tissue frozen at euthanasia in tissue molds containing Tissue Tek® 
O.C.T. (Sakura Fintek Inc, Torrence, CA) and then dissected into compartments by laser 
capture microscopy. We will assess gene regulation (qRT-PCR) and protein expression 
(IHC) for the following genes: CYP17, HSD3β1, and SULT2A1. 
 
5) Does the adipose tissue of obese OSS gilts have increased gene expression of 
HSD3β1, CYP17 and HSD17β4? 
The goal of this experiment is to assess steroidogenic enzyme gene expression 
in Sub-Q and abdominal adipose tissue. Adipose tissue harvested from pigs at 
euthanasia will be divided three ways: frozen in RNA-later (Quiagen Inc), snap-frozen, 
and placed in 10% neutral buffered formalin. Adipose tissue saved in formalin will be 
utilized for IHC for HSD3β1, CYP17 and HSD17β4 protein expression. Snap frozen 
adipose tissue will be used for western blots for HSD3β1, CYP17 and HSD17β4 protein 
  114 
expression. Tissue saved in RNA-later will be utilized for qRT-PCR to assess the gene 
expression of HSD3β1, CYP17 and HSD17β4.  
 
Figure 23. Revised model illustrating known pathologies in the obese OSS sow (S) and 
gilt (G) models of the obese phenotype of PCOS with concomitant MetS. Solid, thick 
arrows indicate hypothesized downstream effects of the strengths of the model, obesity 
and insulin resistance, on reproductive and endocrine physiology. Dashed arrows 
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indicate unknown links in the pathophysiology of the whole animal model, some of which 
will be explored as future research aims.   
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